PART
II — OFFERING CIRCULAR
An
Offering Circular pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information
contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers
to buy be accepted prior to the time an Offering Circular which is not designated as a Preliminary Offering Circular is delivered and
the Offering Circular filed with the Commission becomes qualified. This Preliminary Offering Circular shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any state in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the laws of any such state. We may elect to satisfy our obligation
to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains
the URL where the Final Offering Circular or the Offering Circular in which such Final Offering Circular was filed may be obtained.
Preliminary
Offering Circular |
Subject
to Completion, Dated August 9, 2024 |
MEDICAL
CARE TECHNOLOGIES, INC.
a
Nevada Corporation
1910
S Stapley Drive
Suite
221
Mesa,
AZ 85204
Up
to $1,000,000.00 of Common Stock
Medical
Care Technologies Inc., a Nevada corporation (the “Company” or “MDCE”) is offering investors
(the “Offering”) the opportunity to purchase MDCE common shares (the “Shares”). The Shares will
be sold at per share between $.0005 and $.01, for a maximum amount of $1,000,000 (the “Maximum Amount”). This Offering
is being conducted pursuant to Tier 1 of Regulation A. The Shares are highly speculative securities, see “Risk Factors” beginning
on page 11.
| |
Price to Public (1) | |
Underwriting discount and commissions (2) | |
Proceeds to issuer (3) |
Per Share | |
$ | (between 0.0005
and 0.01) | | |
$ | 0.00 | | |
$ | (between 0.0005
and 0.01) | |
Total Minimum | |
$ | 1,000.00 | | |
$ | 0.00 | | |
$ | 1,000.00 | |
Total Maximum | |
$ | 1,000,000.00 | | |
$ | 0.00 | | |
$ | 1,000,000.00 | |
| |
| | | |
| | | |
| | |
(1)
Please refer to the section entitled “Description of Shares” on page 33 for a Description
of the Shares being Offered.
(2)
The Shares will be offered and sold by our officers and directors who will not receive any
direct compensation in connection therewith. However, we reserve the right to engage broker-dealers registered under Section 15 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”) and who are FINRA members to participate in
the offer and sale of the Shares and to pay to such persons, if any, cash commissions of up to ten percent (10%) of the gross proceeds
from the sales of Shares placed by such persons.
(3)
We estimate that our total Offering expenses, including commissions, will be approximately
$50,000. See “Plan of Distribution.”
The
Offering will be made on “best-efforts” continuous basis as provided by Rule 251(d)(3)(i)(F) basis through a Tier 1 offering
pursuant to Regulation A (“Regulation A”). We expect to commence the sale of the Shares within two days of the date
on which the Offering Circular of which this Offering Circular is a part (the “Offering Circular”) is
qualified (the “Qualification Date”) by the United States Securities and Exchange Commission (the “SEC”).
This
Offering will terminate on the earlier of (i) one year from the Qualification Date; (ii) the date on which the Maximum Amount is sold,
or (iii) the date that the Offering is earlier terminated by us in our sole discretion (collectively, the “Termination Date”).
The minimum investment amount from an investor is $1,000.00; however, we expressly reserve the right to waive this minimum at the sole
discretion of our management. See “Description of Shares” on page 33 for a discussion of certain items required by Item 14
of Part II of Form 1-A. We will hold closings at any time at the Company’s discretion upon the receipt of investors’ subscriptions
and acceptance of such subscriptions by the Company. If, on the initial closing date, we have sold less than the Maximum Amount, then
we may hold one or more additional closings for additional sales of Shares, until the earlier of (i) the sale of the Maximum Amount or
(ii) the Termination Date. There is no aggregate minimum requirement for the Offering to become effective; therefore, we reserve the
right, subject to applicable securities laws, to begin applying the proceeds from the Offering towards our business strategy, including,
without limitation, research, and development expenses, offering expenses, working capital, and general corporate purposes and other
uses, as more specifically set forth in the “Use of Proceeds” section of this Offering Circular.
Subscriptions
for Shares are irrevocable, and the purchase price is non-refundable, unless the Company rejects a subscription, as expressly stated
in this Offering Circular. All proceeds received by us from subscribers in this Offering will be available for use by us upon our acceptance
of subscriptions for the Shares. We expect to commence the sale of Shares of our Common Stock in July 2024, or shortly thereafter.
The
Company currently has two (2) classes of voting stock, Common Stock, Special 2021 Series A Preferred Stock. This Offering relates to
the sale of shares of our Common Stock, which carry one vote per share of Common Stock. When voting as a single group with the Company’s
Common Stock, our Special 2021 Series A Preferred Stock has the voting power equal to 60% of all issued and outstanding shares. Accordingly,
holders of the Special 2021 Series A Preferred Stock will, for the foreseeable future, have voting control over such matters requiring
approval by shareholders, including, but not limited to, the election of directors and the approval of mergers or other business combination
transactions. Our CEO holds the single outstanding share of Special 2021 Series A Preferred Stock. For a complete description of the
ownership by Management of the issued and outstanding shares of both our Common and Preferred Stock, please see the “Securities
Ownership” section of this Offering Circular.
Class
of Stock (Par Value) |
Voting |
Conversion |
Total
Authorized |
Issued
and Outstanding
Pre-Offering |
Issued
and Outstanding Post-Offering |
Common
Stock ($0.00001) |
1-for-1
|
N/A |
7,979,999,990 |
3,209,575,220 |
5,209,575,220
(1) |
Special
2021 Series A Preferred Stock
($0.00001) |
60%
of the issued and outstanding stock |
3,000,000
shares of common stock |
1 |
1 |
1 |
| (1) | This
assumes 100% of the shares offered in the Offering are sold at the minimum sales price of
$.0005 per share. |
For
a complete description of both the Common Stock and Series A Preferred Stock, please see the “Description of Shares” section
of this Offering Circular.
Upon
the closing of this offering, our officers and directors will retain controlling voting power in our company. As a result, our officers
and directors will have the ability to substantially influence all matters submitted to our stockholders for approval and to substantially
influence or control our operations, management, and affairs.
Our
common stock is quoted on the Pink Tier of OTC Markets, which is operated by OTC Markets Group, Inc. (OTC Markets), under the ticker
symbol MDCE. On July 23, 2024, the closing price of our common stock was $0.0023 per share.
Investing
in the Offered Shares is speculative and involves substantial risks. You should purchase Offered Shares only if you can afford a complete
loss of your investment. See Risk Factors, beginning on page 11, for a discussion of certain risks that you should consider before purchasing
any of the Offered Shares.
THE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE
TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE
SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT
DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.
The
use of projections or forecasts in this offering is prohibited. No person is permitted to make any oral or written predictions about
the benefits you will receive from an investment in the Offered Shares.
This
Offering Circular is following the offering circular format described in Part II (a)(1)(ii) of Form 1-A.
Table
Of Contents
FORWARD
LOOKING STATEMENTS
Some
of the statements in this Offering Circular constitute forward-looking statements. These statements relate to future events or our future
financial performance, plans, and objectives. In some cases, you can identify forward- looking statements by terminology such as “proposed,”
“yet,” “assuming,” “may,” “should,” “expect,” “intend,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,”
“will,” and similar words or phrases or the negative or other variations thereof or comparable terminology. All forward-looking
statements are predictions or projections and involve known and unknown risks, estimates, assumptions, uncertainties, and other factors
that may cause our actual transactions, results, performance, achievements, and outcomes to differ adversely from those expressed or
implied by such forward-looking statements.
You
should not place undue reliance on forward-looking statements. The cautionary statements set forth in this Offering Circular, including
in “Risk Factors” and elsewhere, identify important factors that you should consider in evaluating the Company’s forward-looking
statements. These factors include, among other things:
|
• |
Our ability to implement our proposed business plan; |
|
• |
National, international,
and local economic and business conditions that could affect our business; |
|
• |
Markets for our Shares; |
|
• |
Our cash flows or lack
thereof; |
|
• |
Our operating performance; |
|
• |
Our financing activities; |
|
• |
Industry developments affecting
our business, financial condition, and results of operations; |
|
• |
Our ability to compete
effectively; and |
|
• |
Governmental
approvals, actions and initiatives and changes in laws and regulations or the interpretation thereof, including without limitation
tax laws, regulations and interpretations by the SEC, States, and self-regulatory organizations, including without limitation, FINRA. |
Although
we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future plans, transactions,
results, performance, achievements, or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in
our forward-looking statements will be attained or that deviations from them will not be material and adverse. We undertake no obligation,
other than as may be required by law, to re-issue this Offering Circular or otherwise make public statements in order to update its forward-looking
statements beyond the date of this Offering Circular.
Please
read this offering circular carefully. It describes our business, our financial condition, and results of operations. We have prepared
this offering circular so that you will have the information necessary to make an informed investment decision.
You
should rely only on information contained in this offering circular. We have not authorized any other person to provide you with different
information. This offering circular is not an offer to sell, nor is it seeking an offer to buy, these securities in any state where the
offer or sale is not permitted. The information in this offering circular is complete and accurate as of the date on the front cover,
but the information may have changed since that date.
IMPLICATIONS
OF BEING AN EMERGING GROWTH COMPANY
We
are not subject to the ongoing reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
because we are not registering our securities under the Exchange Act. Rather, we will be subject to the more limited reporting requirements
under Regulation A, including the obligation to electronically file:
|
• |
annual
reports (including disclosure relating to our business operations for the preceding three fiscal years, or, if in existence for less
than three years, since inception, related party transactions, beneficial ownership of the issuer’s securities, executive officers
and directors and certain executive compensation information, management’s discussion and analysis (“MD&A”)
of the issuer’s liquidity, capital resources, and results of operations, and two years of audited financial statements), |
|
• |
semiannual
reports (including disclosure primarily relating to the issuer’s interim financial statements and MD&A, and |
|
• |
current
reports for certain material events. |
In
addition, at any time after completing reporting for the fiscal year in which our offering statement was qualified, if the securities
of each class to which this offering statement relates are held of record by fewer than 300 persons and offers or sales are not ongoing,
we may immediately suspend our ongoing reporting obligations under Regulation A.
If
and when we become subject to the ongoing reporting requirements of the Exchange Act, as an issuer with less than $1.235 billion in
total annual gross revenues during our last fiscal year, we will qualify as an “emerging growth company” under the
Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and this status will be significant. If we qualify as an
emerging growth company, we may take advantage of certain reduced reporting requirements and would be relieved of certain other
significant requirements that are otherwise generally applicable to public companies. As an emerging growth company we:
| • | would
not be required to obtain an auditor attestation on our internal controls over financial
reporting pursuant to the Sarbanes-Oxley Act of 2002; |
| • | would
not be required to provide a detailed narrative disclosure discussing our compensation principles,
objectives and elements and analyzing how those elements fit with our principles and objectives
(commonly referred to as “compensation discussion and analysis”); |
| • | would
not be required to obtain a non-binding advisory vote from our stockholders on executive
compensation or golden parachute arrangements (commonly referred to as the “say-on-pay,”
“say-on-frequency” and “say-on-golden parachute” votes); |
| • | would
be exempt from certain executive compensation disclosure provisions requiring a pay-for-
performance graph and CEO pay ratio disclosure; |
| • | would
be able to present only two years of audited financial statements and only two years of related
Management’s Discussion and Analysis of Financial Condition and Results of Operations,
or MD&A; and |
| • | would
be eligible to claim longer phase-in periods for the adoption of new or revised financial
accounting standards. |
We
intend to take advantage of all reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption
of new or revised financial accounting standards under Section 107 of the JOBS Act. Our election to use the phase-in periods may make
it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have
opted out of the phase-in periods under Section 107 of the JOBS Act.
Under
the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions for up to five years after our
initial sale of common equity pursuant to a registration statement declared effective under the Securities Act, or such earlier time
that we no longer meet the definition of an emerging growth company. Note that this offering, while a
public offering, is not a sale
of common equity pursuant to a registration statement since the offering is conducted pursuant to an exemption from the registration
requirements. In this regard, the JOBS Act provides that we would cease to be an “emerging growth company” if we have more
than $1.235 billion in annual revenues, have more than $700 million in market value of our common stock held by non-affiliates, or issue
more than $1 billion in principal amount of non-convertible debt over a three-year period.
Certain
of these reduced reporting requirements and exemptions may also be available to us if we qualify, once listed, as a “smaller reporting
company” under the SEC’s rules. For instance, smaller reporting companies are not required to obtain an auditor attestation
on their assessment of internal control over financial reporting; are not required to provide a compensation discussion and analysis;
are not required to provide a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial
statements
and related MD&A disclosure.
OFFERING
CIRCULAR SUMMARY
This
summary provides an overview of selected information contained elsewhere in this offering circular. It does not contain all the information
you should consider before making a decision to purchase the Shares we are offering. You should very carefully and thoroughly read the
more detailed information in this offering circular and review our financial statements contained herein.
The
Company’s operations are subject to all the risks inherent in the establishment of a new business enterprise. The likelihood of
our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection
with the formation of any business. Our lack of a significant and relevant operating history makes it difficult to predict future operating
results.
OVERVIEW
Overview
Infinite
Auctions is an online auction house that provides an online platform for memorabilia collectors and professional athletes to consign
and sell high valued collectibles in a secure online auction format. Since 2016 we have sold more than $13.5 million in sports collectibles.
We currently specialize in the auctioning of game worn sports memorabilia that includes jerseys, helmets, bats and other items worn or
used by athletes in professional sporting events. We also auction high-end sports cards, trading cards, fine autographs, Americana and
other valuable antiquities. Our auction service gives collectors of high value memorabilia a safe environment to sell their collectibles
where the prices are substantially higher than you would see on mainstream online auction sites like Ebay and much safer than meeting
a potential buyer on the street with a bag of cash or facing the risk of digital payment return fraud. In addition to our regular online
auction services, our private sale brokering program connects sellers and buyers outside of auction for quicker sales. We often set records
with our private sales as we recently sold a Tom Brady game worn jersey for a record $500,000. We also actively make purchases both privately
and through public auctions for later resale as the collectibles industry continues to be in a considerable appreciation cycle over the
last several decades
We
expect to use the proceeds of this offering for general development, working capital, and marketing as well as general and administrative
expenses. We expect to commence offering Shares in August 2024. See “Use of Proceeds” at page 17.
Our
business headquarters are located at 530 E. Hunt Hwy. Suite 103-225 San Tan Valley, AZ. 85143, Email: info@infiniteauctions.com, Tel:
480-988-5847, our website can be found at www.infiniteauctions.com.
Our
securities counsel is Jonathan D. Leinwand, P.A., 18305 Biscayne Blvd, Suite 200, Aventura, FL 33180. Their phone number is 954-903-7856.
SUMMARY
OF THE OFFERING
Issuer | |
Medical Care Technologies, Inc., a Nevada corporation. |
Securities Offered | |
Up
to 2,000,000,000 shares of the Company’s common stock par value $.00001 per share. |
Offering Amount | |
We are offering a maximum of $1,000,000 of Shares (the “Maximum Amount”). |
Offering Price | |
$.0005 to $0.01 per Share. The minimum investment is $1,000.00. |
Commencement of the Offering | |
We expect to commence the sale of the Shares within two days following the Qualification Date. |
Number of shares outstanding before the Offering | |
3,209,575,220 shares as of the date hereof. |
Number of shares outstanding after the Offering | |
5,209,575,220 Shares will be issued and outstanding after the offering of the Shares if all the Shares in this offering being offered are sold at the lowest price in the price range of $.0005 per share. |
Issuer | |
There is no aggregate minimum requirement for the Offering to become effective; therefore, we reserve the right, subject to applicable securities laws, to begin applying the proceeds from the Offering towards our business strategy, including, without limitation, research, and development expenses, offering expenses, working capital, and general corporate purposes and other uses, as more specifically set forth in the “Use of Proceeds” section of this Offering Circular. |
Use of Proceeds | |
The Company intends to use the proceeds of this offering for working capital, marketing, and general and administrative purposes. See ‘Use of Proceeds’ section for details at page 17. |
Offering Amount | |
This Offering will terminate on the earlier of (i) one year from the Qualification Date; (ii) the date on which the Maximum Amount is sold, or (iii) the date that the Offering is earlier terminated by us, in our sole discretion. |
Closing | |
The Shares will be issued in one or more closings (the “Closings”). After the Initial Closing, the Offering will continue on a continuous basis, and we may have one or more additional Closings until the earlier of the Termination Date or the receipt and acceptance of subscription funds equal to the Maximum Amount. |
Best Efforts Offering | |
The Offering is being conducted by our Board of Directors on a “best efforts basis. Our Board of Directors will not receive any direct compensation for sales of our Shares. However, we reserve the right to engage broker-dealers registered under Section 15 of the Exchange Act (“Selling Agents”), and who are FINRA members to participate in the offer and sale of the Shares and to pay to such Selling Agents, if any, cash commissions of up to 7% of the gross proceeds from the sales of Shares placed by such Selling Agents and agent warrants (“Agent Shares”). Our Board of Directors, officers, employees, and affiliates (as defined in the Securities Act) may, but have no obligation to, solicit or purchase Shares in the Offering and all such Shares so sold or purchased shall be counted toward the Maximum Amount. We reserve the right to reject a subscription to purchase Shares, in whole or in part in our sole discretion. If a subscription is so rejected, in whole or in part, we will promptly return the funds submitted with such rejected subscription, or the rejected portion thereof, to the investor without interest thereon or deduction therefrom. |
Subscription Procedures | |
To subscribe for Shares, complete and execute the Subscription Agreement accompanying this Offering Circular and deliver it to us before the Termination Date, together with full payment for all Shares subscribed in accordance with the instructions provided in the Subscription Agreement. Once you subscribe, subject to acceptance by us, your subscription is irrevocable. We have the right, at any time prior to the issuance of the Shares, to reject subscriptions in our sole discretion. |
Risk Factors | |
Investing in the Shares involves a high degree of risk. See “Risk Factors, beginning on page 11. You should read the Risk Factors section of, and all the other information set forth in, this Offering Circular to consider carefully before deciding to purchase any Shares in this offering. |
You
should rely only upon the information contained in this offering circular. The Company has not authorized anyone to provide you with
information, including projections of performance, different from that which is contained in this offering circular. The Company is offering
to sell the Shares and seeking offers only in jurisdictions where offers and sales are permitted. The information contained here is accurate
only as of the date of this offering circular, regardless of the time of delivery of this offering circular or of any sale of the Shares.
There
is no aggregate minimum requirement for the Offering to become effective; therefore, we reserve the right, subject to applicable securities
laws, to begin applying the proceeds from the Offering towards our business strategy, including, without limitation, research, and development
expenses, offering expenses, working capital, and general corporate purposes and other uses, as more specifically set forth in the “Use
of Proceeds” section of this Offering Circular. Upon the approval of any subscription to this Offering Circular, the Company shall
immediately deposit said proceeds into the bank account of the Company and may dispose of the proceeds in accordance with the Use of
Proceeds.
In
order to subscribe to purchase the Shares, a prospective investor must complete a subscription agreement and send payment by check, wire
transfer, or ACH. Investors must answer certain questions to determine compliance with the investment limitation set forth in Regulation
A Rule 251(d)(2)(i)(C) under the Securities Act of 1933, which states that in offerings such as this one, where the securities will not
be listed on a registered national securities exchange upon qualification, the aggregate purchase price to be paid by the investor for
the securities cannot exceed 10% of the greater of the investor’s annual income or net worth. In the case of an investor who is
not a natural person, revenues, or net assets for the investors most recently completed fiscal year are used instead.
The
Company has not currently engaged any party for the public relations or promotion of this offering.
The
information contained on our website is not incorporated by reference into this Offering Circular, and you should not consider information
contained on our website to be part of this Offering Circular.
The
Company currently has two (2) classes of voting stock, Common Stock and Special 2021 Series A Preferred Stock. This Offering relates
to the sale of shares of our Common Stock, which carry one vote per share of Common Stock, in contrast our Series A Preferred Stock has
voting rights equivalent to 60% of the Company’s issued and outstanding shares when voting as a single class. Accordingly, holders
of the Series A Preferred Stock will, for the foreseeable future, have voting control over such matters requiring approval by shareholders,
including, but not limited to, the election of directors and the approval of mergers or other business combination transactions. Our
CEO and a Director, Marshall Perkins III, prior to this offering controls the majority of the total voting power of the Company including
1,980,000,000 shares of common stock (approximately 61.7%) and 100% of the Series A Preferred Stock. At the conclusion of this Offering,
assuming 100% of the shares offered hereby are sold, Mr. Perksins will continue to control the majority of the total voting power of
the Company. Therefore he alone significantly influences all matters requiring approval by shareholders, including the election of directors
and the approval of mergers or other business combination transactions. For a complete description of the ownership by Management of
the issued and outstanding shares of both our Common and Preferred Stock, please see the “Securities Ownership” section of
this Offering Circular.
Class
of Stock (Par Value) |
Voting |
Conversion |
Total
Authorized |
Issued
and Outstanding
Pre-Offering |
Issued
and Outstanding Post-Offering |
Common
Stock ($0.00001) |
1-for-1
|
N/A |
7,979,999,990 |
3,209,575,220 |
5,209,575,220
(1) |
Special
2021 Series A Preferred Stock ($0.00001) |
60%
of the issued and outstanding stock |
3,000,000
shares of common stock |
1 |
1 |
1 |
| (1) | This
assumes 100% of the shares offered by the Offering are sold at the low-end of the price range.. |
For
a complete description of both the Common Stock and Series A Preferred Stock, please see the “Description of Shares” section
of this Offering Circular.
CONTINUOUS
OFFERING
Under
Rule 251(d)(3) to Regulation A, the following types of continuous or delayed offerings are permitted, among others: (1) securities offered
or sold by or on behalf of a person other than the issuer or its subsidiary or a person of which the issuer is a subsidiary; (2) securities
issued upon conversion of other outstanding securities; or (3) securities that are part of an offering which commences within two calendar
days after the qualification date. These may be offered on a continuous basis and may continue to be offered for a period in excess of
30 days from the date of initial qualification. They may be offered in an amount that, at the time the offering statement is qualified,
is reasonably expected to be offered and sold within two years from the initial qualification date. No securities will be offered or
sold “at the market.” The supplement will not, in the aggregate, represent any change from the maximum aggregate offering
price calculable using the information in the qualified offering statement. This information will be filed no later than two business
days following the earlier of the date of determination of such pricing information or the date of first use of the offering circular
after qualification.
Subscriptions
are irrevocable, and the purchase price is non-refundable as expressly stated in this Offering Circular. The Company, by determination
of the Board of Directors, in its sole discretion, may issue the Securities under this Offering for cash, promissory notes, services,
and/or other consideration without notice to subscribers. All proceeds received by the Company from subscribers for this Offering will
be available for use by the Company upon acceptance of subscriptions for the Securities by the Company.
DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling
the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.
RISK
FACTORS
Please
consider the following risk factors and other information in this offering circular relating to our business and prospects before deciding
to invest in our Shares. This offering and any investment in our Shares involves a high degree of risk. You should carefully consider
the risks described below and all of the information contained in this offering circular before deciding whether to purchase our Shares.
If any of the following risks actually occur, our business, financial condition and results of operations could be harmed, and you may
lose all or part of your investment. The Company should be viewed as a high-risk investment and speculative in nature. An investment
in our Shares may result in a complete loss of the invested amount. Please consider the following risk factors before deciding to invest
in our Shares.
Financial
Projections. Any financial projections are based upon what the Company believes to be reasonable assumptions concerning certain
factors affecting probable future operations of the Company. Despite these future projections, no assurances can be made that these projections
will prove to be accurate, and potential investors are cautioned against placing excessive reliance on such projections in deciding whether
to invest in the Company. Market conditions and capital costs are very volatile and may cause the Company to seek additional capital
or alternative forms of capital. In turn, this could result in a dilution of an Investor’s ownership interest in the Company.
Arbitrary
Offering Price.
The
offering price of $0.01 per Share has been arbitrarily set by the Company and is not based upon earnings, operating history, assets,
book value, or any other recognized criteria of value. No independent opinion has been obtained in the determination of the offering
price.
We
may fail to establish and maintain strategic relationships.
We
believe that the establishment of strategic partnerships will greatly benefit the growth of our business, and we intend to seek out and
enter strategic alliances. We may not be able to enter these strategic partnerships on commercially reasonable terms, or at all. Even
if we enter strategic alliances, our partners may not attract significant numbers of clients or otherwise prove advantageous to our business.
Our inability to enter new strategic alliances could have a material and adverse effect on our business.
If
we were to lose the services of Mr. Perkins, we may not be able to execute our business strategy.
We
currently depend on the continued services and performance of the key member of our management team, comprised solely of Mr. Perkins.
His leadership has played an integral role in our company. The loss of the key member of our management team could disrupt our operations
and have an adverse effect on our ability to grow our business. In addition, competition for senior executives and key personnel in our
industry is intense, and we may be unable to retain our senior executives and key personnel or attract and retain new senior executives
and key personnel in the future, in which case our business may be severely disrupted.
Risk
of Being a “Controlled Company” Post-Offering
Potential
investors should be aware that upon completion of this offering, Marshall Perkins will maintain significant influence over the company,
rendering Medical Care Technologies, Inc. a “controlled company” within the meaning of the securities rules and regulations.
Mr. Perkins, through his direct ownership and control of the Special 2021 Series A Preferred Stock, will possess voting power equivalent
to 60% of the total voting power of all outstanding shares of our stock, enabling him to control the election of our directors and the
outcome of corporate actions requiring shareholder approval, notwithstanding the number of shares sold to the public in this offering.
This concentration of ownership might discourage, delay, or prevent a change in control of the company, which could deprive our shareholders
of an opportunity to receive a premium for their shares as part of a sale of our company and might reduce the price of our common stock.
This control could also have the
effect of delaying or preventing a change in control of Medical Care Technologies, Inc., even if such
a change of control would benefit our other shareholders.
If
we are unable to hire qualified personnel and retain or motivate key personnel, we may not be able to grow effectively.
Our
future success depends on our continuing ability to identify, hire, develop, motivate, and retain skilled personnel for all areas of
our organization. Our continued ability to compete effectively depends on our ability to attract new employees and to retain and motivate
our existing employees.
A
decline in general economic conditions could have a material adverse effect on our business, financial condition, and results of operations.
Our
operating and financial performance may be adversely affected by a variety of factors that influence the general economy. It is our
opinion that in the event of an economic slowdown, spending habits of both consumers and businesses could be adversely affected, and
we could experience lower net sales than expected on a quarterly or annual basis which could have a material adverse effect on our
business, financial condition, and results of operations. The success of the Company
The
continued demand for collectibles is unknown.
Demand
for Collectibles depends to a large extent on general, economic, political, and social conditions in a given market as well as the tastes
of the collector community and in the case of sports, the general fan community resulting in changes of which Collectible Assets are
most sought after. There are several key factors that will potentially impact the Company’s operating results going forward, including
our ability to continue to source high quality collectibles at reasonable prices and the continued demand for collectibles, which is
unknown. The current level of popularity of sports memorabilia may not be sustained.
If
any of our items are determined to be forged it could hurt our reputation and hinder our ability to continue to sell collectibles.
We
are highly reliant on the trusted name of the brand, retailer, authenticator or other conduit to ensure the integrity of the items we
sell. While there is no guarantee that an item will be free of fraud, we attempt to mitigate this risk by having the item graded
or authenticated by a reputable firm. In the event of an authenticity claim against an authenticated item, the Company may have
recourse for reimbursement from the authenticator, although there can be no guarantee of the Company’s ability to collect or the
authenticator’s ability to pay.
Furthermore,
authenticators may occasionally make mistakes by either giving their approval or grade to a counterfeit card or piece of memorabilia.
Sometimes this mistake is not uncovered until years later when evidence to the contrary surfaces or updated scientific methods
are applied. The Company may not have recourse, if such an event occurs. Finally, there is reputational risk of the authenticator,
which may fall out of favor with collectors, which may impact the value of all items authenticated by the particular authenticator.
We
may need additional capital in the future in order to expand our business.
Our
future capital requirements may be substantial, particularly as we continue to develop our business. Although we believe that, based
on our current level of operations, our existing cash, cash equivalents and equity securities will provide adequate funds for ongoing
operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital
if our current plans and assumptions change.
In
addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have
sufficient funds for our current or future operating plans. We may seek to obtain such additional capital through equity offerings, debt
financings, credit facilities and/or strategic collaborations. If future financings involve the issuance of equity securities, our existing
stockholders will suffer dilution. If we raise debt financing or enter into credit facilities, we may be subject to restrictive covenants
that limit our ability to conduct our business. We may not be able to raise sufficient
additional funds on terms that are favorable to
us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to
control operating costs, our ability to fund our operations, take advantage of strategic opportunities, or otherwise respond to competitive
pressures could be significantly limited. If adequate funds are not available, we will not be able to successfully execute our business
plan or continue our business.
Competitors
and potential competitors who have greater resources and experience than we do may develop products and technologies that make ours obsolete
or may use their greater resources to gain market share at our expense.
Our
future success will depend on our ability to maintain a competitive position with respect to access to popular classes of collectibles
and our ability to provide a platform and a marketplace where sellers can efficiently sell their collectibles. There are several competitors
with significantly more resources than the Company, who are running auctions more frequently than then we are. Additionally, as they
are generally selling more merchandise, they have a larger selection of items available that attracts buyers to their platforms.
Additionally,
self-service platforms such as eBay operate more efficiently at a lower cost than we can. We have to demonstrate the value of our services
to sellers so that they do not choose such self-service platforms.
Ultimately,
our ability to compete successfully in any of these markets will depend on our ability to attract buyers to the Infinite Auctions site.
Our
competitors may be able to develop competing and/or superior technologies and processes and compete more aggressively and sustain that
competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological
advances or entirely different approaches developed by one or more of our competitors.
Our
limited resources relative to many of our competitors may cause us to fail to anticipate or respond adequately to new developments and
other competitive pressures. This failure could reduce our competitiveness and market share, adversely affect our results of operations
and financial position, and prevent us from obtaining or maintaining profitability.
We
expect our quarterly financial results to fluctuate.
We
expect our revenue and operating results to vary significantly from quarter to quarter due to a number of factors, including changes
in:
|
• |
General economic conditions; |
|
• |
The number of clients for
our business consulting services; |
|
• |
Our ability to retain,
grow our business and attract new clients; |
|
• |
Administrative costs; and, |
|
• |
Advertising and other marketing
costs. |
As
a result of the variability of these and other factors, our operating results in future quarters may be below the expectations of public
market analysts and investors.
There
has been only a limited public market for our Shares and an active trading market for our Shares may not develop following this offering.
There
has not been any broad public market for our Shares, and an active trading market may not develop or be sustained. Shares of our common
stock may not be able to be resold at or above the initial public offering price. The initial public offering price of our Shares has
been determined arbitrarily by management without regard to earnings, book value, or other traditional indication of value. Our Shares
may trade below the initial public offering price following the completion of this offering. The market value of our Shares could be
substantially affected by general market conditions, including the extent to which a
secondary market develops for our Shares following
the completion of this offering, the extent of institutional investor interest in us, the general reputation of companies in the biotransformation
industry and the attractiveness of their equity securities in comparison to other equity securities, our financial performance and general
stock market conditions.
The
market price and trading volume of our Shares may be volatile following this offering.
The
trading price of our Shares may be volatile. In addition, the trading volume in our Shares may fluctuate and cause significant price
variations to occur. If the trading price of our Shares declines significantly, you may be unable to resell your Shares at or above the
public offering price. Some of the factors that could negatively affect our share price or result in fluctuations in the price or trading
volume of our Shares include:
|
• |
actual or anticipated variations
in our quarterly operating results or dividends; |
|
• |
changes in our funds from
operations or income estimates; |
|
• |
publication of research
reports about us or our industry; |
|
• |
changes in market valuations
of similar companies; |
|
• |
adverse market reaction
to any additional debt we incur in the future; |
|
• |
additions or departures
of key management personnel; |
|
• |
actions by institutional
stockholders; |
|
• |
speculation in the press
or investment community; |
|
• |
the realization of any
of the other risk factors presented in this offering circular; |
|
• |
the extent of investor
interest in our securities; |
|
• |
investor confidence in
the stock markets, generally; |
|
• |
future equity issuances; |
|
• |
failure to meet income
estimates; and |
|
• |
general market and economic
conditions. |
In
the past, securities class-action litigation has often been instituted against companies following periods of volatility in the price
of their Shares. This type of litigation could result in substantial costs and divert our management’s attention and resources,
which could have an adverse effect on our financial condition, results of operations, cash flow and trading price of our Shares.
Our
Shares are “Penny Stock,” which impairs trading liquidity.
Disclosure
requirements pertaining to penny stocks may reduce the level of trading activity in the market for our Shares and investors may find
it difficult to sell their Shares. The SEC has rules that regulate broker/dealer practices in connection with transactions in “penny
stocks”. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain
national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions
in that security is provided by the exchange or system). The penny stock rules require a broker/dealer, prior to a transaction in a penny
stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that provides information
about penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide the operator with
current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction, and
monthly account statements showing the market value of each penny stock held in the operator’s account. The bid and offer quotations,
and the broker/dealer and salesperson compensation information, must be given to the operator orally or in writing prior to effecting
the transaction and must be given to the operator in writing before or with the operator’s confirmation.
As
an “Emerging Growth Company” any decision to comply with the reduced disclosure requirements applicable to emerging growth
companies could make our Shares less attractive to investors.
We
are an “emerging growth company,” as defined in the JOBS Act, and, for as long as we continue to be an “emerging growth
company,” we may choose to take advantage of exemptions from various reporting requirements applicable to other
public companies
but not to “emerging growth companies,” including, but not limited to, not being required to comply with the auditor attestation
requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our
periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and shareholder approval of any golden parachute payments not previously approved. We could be an “emerging growth company”
for up to five years, or until the earliest of (i) the last day of the first fiscal year in which our annual gross revenues exceed $1
billion,
(ii)
the date that we become a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, which would occur if
the market value of our Shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed
second fiscal quarter, or (iii) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three
year period.
In
addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended
transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other
words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise
apply to private companies. We have elected to opt into the extended transition period for complying with the revised accounting standards.
Our
status as an “Emerging Growth Company” under the JOBS Act of 2012 may make it more difficult to raise capital.
Because
of the exemptions from various reporting requirements provided to us as an “emerging growth company” and because we will
have an extended transition period for complying with new or revised financial accounting standards, we may be less attractive to investors,
and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with
other companies in our industry if they believe that our financial accounting is not as transparent as other companies in our industry.
If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially
and adversely affected.
We
will not have reporting obligations under Sections 14 or 16 of the Securities Exchange Act of 1934, nor will any shareholders have reporting
requirements of Regulation 13D or 13G.
So
long as our common Shares are not registered under the Exchange Act, our directors and executive officers and beneficial holders of 10%
or more of our outstanding common Shares will not be subject to Section 16 of the Exchange Act. Section 16(a) of the Exchange Act requires
executive officers and directs, and persons who beneficially own more than 10% of a registered class of equity securities to file with
the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of
common Shares and other equity securities, on Forms 3, 4 and 5, respectively. Such information about our directors, executive officers,
and beneficial holders will only be available through this (and any subsequent) offering circular, and periodic reports we file there
under.
As
long as our common Shares are not registered under the Exchange Act, we will not be subject to Section 14 of the Exchange Act, which,
among other things, prohibits companies that have securities registered under the Exchange Act from soliciting proxies or consents from
shareholders without furnishing to shareholders and filing with the Securities and Exchange Commission a proxy statement and form of
proxy complying with the proxy rules.
In
addition, so long as our common Shares are not registered under the Exchange Act, our Company will not be subject to the reporting requirements
of Regulation 13D and Regulation 13G, which requires the disclosure of any person who, after acquiring directly or indirectly the beneficial
ownership of any equity securities of a class, becomes, directly or indirectly, the beneficial owner of more than five (5%) of the class.
Investors
cannot withdraw funds once invested and will not receive a refund.
Investors
do not have the right to withdraw invested funds. Subscription payments will be paid to the Company and held in our corporate bank account
if the Subscription Agreements are in good order and the Company accepts the investor’s investment. Therefore, once an investment
is made, investors will not have the use or right to return of such funds.
Risk
of losing one’s investment.
If
our securities are not eligible for continued quotation on the OTC Marketplace, or a robust public trading market does not develop, purchasers
of the shares of common stock may have difficulty selling or be unable to sell their securities, rendering their shares effectively worthless
and resulting in a partial or complete loss of their investment.
Our
Management does not have any prior experience conducting a best effort offering, and our best-efforts offering does not require a minimum
amount to be raised. As a result, we may not be able to raise enough funds to commence and sustain our business and our investors may
lose their entire investment.
Management
does not have any experience conducting a best-efforts offering. Consequently, we may not be able to raise the funds needed to commence
business operations. Also, the best-efforts offering does not require a minimum amount to be raised. If we are not able to raise sufficient
funds, we may not be able to fund our operations as planned, and our business will suffer, and your investment may be materially adversely
affected. Our inability to successfully conduct a best-efforts offering could be the basis of your losing your entire investment in us.
We
are selling the shares of this offering without an underwriter and may be unable to sell any shares.
This
offering is self-underwritten, which means that we are not going to engage the services of an underwriter to sell the shares. We intend
to sell our shares through our Management, who will receive no commission. There is no guarantee that he will be able to sell any of
the shares. Unless she is successful in selling all of the shares of our Company’s offering, we may have to seek alternative financing
to implement our business plan.
Investing
in our company is highly speculative and could result in the entire loss of your investment.
Purchasing
the offered shares is highly speculative and involves significant risk. The offered shares should not be purchased by any person who
cannot afford to lose their entire investment. Our business objectives are also speculative, and it is possible that we would be unable
to accomplish them. Our shareholders may be unable to realize a substantial or any return on their purchase of the offered shares and
may lose their entire investment. For this reason, each prospective purchaser of the offered shares should read this prospectus and all
of its exhibits carefully and consult with their attorney, business and/or investment advisor.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain
information contained in this Offering Circular includes forward-looking statements. The statements herein which are not historical reflect
our current expectations and projections about the Company’s future results, performance, liquidity, financial condition, prospects,
and opportunities and are based upon information currently available to the Company and its management and management’s interpretation
of what is believed to be significant factors affecting the business, including many assumptions regarding future events. Such forward-looking
statements include statements regarding, among other things:
|
• |
potential governmental
regulations relating to or that may impact our industry segments; |
|
• |
increased costs or exposure
to liability as a result of changes in laws or regulations applicable to the biotransformation industry; |
|
• |
general volatility of the
capital and credit markets and the market price of our Shares; |
|
• |
exposure to litigation
or other claims; |
|
• |
loss of key personnel; |
|
• |
the risk that we may experience
future net losses; |
|
• |
risks associated with breaches
of our security; |
|
• |
failure to obtain necessary
outside financing on favorable terms, or at all; |
|
• |
risks associated with future
sales of our Shares by existing shareholders or the perception that they intend to sell substantially all of the Shares of our Company
that they hold; |
|
|
• |
risks associated with the
market for our Shares; or |
|
• |
any
of the other risks included in this offering circular, including those set forth under the headings “Risk Factors,” “Board
of Directors’ Discussion and Analysis of Financial Condition and Results of Operations” and “Our Business.” |
Forward-looking
statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use
of the words “will,” “shall,” “may,” “should,” “expect,” “anticipate,”
“estimate,” “believe,” “intend,” “plan,” or “project” or the negative of
these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition,
prospects, and opportunities could differ materially from those expressed in, or implied by, these forward-looking statements as a result
of various risks, uncertainties, and other factors, including the ability to raise sufficient capital to continue the Company’s
operations. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various
factors, including, without limitation, the risks outlined under “Risk Factors” and matters described in this Offering Circular
generally. In light of these risks and uncertainties, there can be no assurance that the forward- looking statements contained in this
Registration Statement will in fact occur.
Accordingly,
prospective investors should not place undue reliance on any forward-looking statements. Except as expressly required by the federal
securities laws, there is no undertaking to publicly update or revise any forward- looking statements, whether as a result of new information,
future events, changed circumstances or any other reason.
The
specific discussions herein about the Company include financial projections and future estimates and expectations about the Company’s
business. The projections, estimates and expectations are presented in this Offering Circular only as a guide about future possibilities
and do not represent actual amounts or assured events. All the projections and estimates are based exclusively on the officers of the
Company’s own assessment of its business, the industry in which it works and the economy at large and other operational factors,
including capital resources and liquidity, financial condition, fulfillment of contracts, and opportunities. The actual results may differ
significantly from the projections.
Prospective
investors should not make an investment decision based solely on the Company’s projections, estimates or expectations.
USE
OF PROCEEDS
Our
offering is being made on a best-efforts basis. There is no aggregate minimum requirement for the Offering to become effective; therefore,
we reserve the right, subject to applicable securities laws, to begin applying the proceeds from the Offering towards our business strategy,
including, without limitation, research, and development expenses, offering expenses, working capital, and general corporate purposes
and other uses, as more specifically set forth in the “Use of Proceeds” section of this Offering Circular. The offering price
per share is $0.01 per share. We expect to use the funds of this offering for operations, working capital, general and administrative
expenses, business development and marketing.
No
proceeds will be used to compensate or make payments to any officers or directors, except for salaries and ordinary business expenses
incurred in the normal course of business, or as set forth under the caption “Executive Compensation.” We reserve the right
to change the intended use of proceeds if necessitated by business conditions or unexpected events.
We
estimate that, at a per share price of $[ ], the net proceeds from the sale of the shares in this Offering will be approximately $1,000,000,
before deducting the estimated offering expenses of approximately $50,000.
We
will utilize the net proceeds from this offering to identify and acquire business opportunities and to continue to refine, develop, and
implement our plan of operation. Some funds will be used for operating expenses and other expenses.
Accordingly,
we expect to use the net proceeds, estimated as discussed above as follows, if we raise the maximum offering amount:
Use |
|
Amount |
|
|
Percentage |
|
R&D Costs |
|
$ |
50,000 |
|
|
|
5.26 |
% |
Business Development |
|
$ |
200,000 |
|
|
|
21.05 |
% |
Working Capital |
|
$ |
400,000 |
|
|
|
42.1 |
% |
Salaries |
|
$ |
250,000 |
|
|
|
26.31 |
% |
Offering Expenses (1) |
|
$ |
50,000 |
|
|
|
5.26 |
% |
TOTAL |
|
$ |
950,000 |
(2) |
|
|
100.00 |
% |
(1)
“Offering Expenses” include projected costs for Legal and Accounting, Publishing/Edgar, and Transfer Agents Fees.
(2)
“Proportional Reduction Based on Amount Raised” - We anticipate that should less than the Maximum Offering Amount
be raised hereunder the expenditures will be reduced proportionately, but the representative spending percentage would remain approximately
the same. For example, if we were only able to raise 50% of the aggregate offering, the percentage of spending would remain the same,
but the Amount set forth above would be reduced by 50%, etc.
The
above figures represent only estimated costs. This expected use of net proceeds from this offering represents our intentions based upon
our current plans and business conditions. The amounts and timing of our actual expenditures may vary significantly depending on numerous
factors, including the status of and results from operations. As a result, our management will retain broad discretion over the allocation
of the net proceeds from this offering. We may find it necessary or advisable to use the net proceeds from this offering for other purposes,
and we will have broad discretion in the application of net proceeds from this offering. Furthermore, we anticipate that we will need
to secure additional funding for the fully implement our business plan. We cannot assure that our assumptions, expected costs and expenses,
and estimates will prove to be accurate or that unforeseen events, problems, or delays will not occur that would require us to seek additional
debt and/or equity funding, which may not be available on favorable terms, or at all. See “Risk Factors” starting on page
11.
Although
our business does not presently generate any cash, we believe that if we raise the Maximum Amount in this Offering, that we will have
sufficient capital to finance our operations at least through the end of 2024. However, if we do not sell the Maximum Amount or if our
operating and development costs are higher than expected, we will need to obtain additional financing prior to that time. Further, we
expect that during and/or after such period, we may be required to raise additional funds to finance our operations until such time that
we can conduct profitable revenue- generating activities. We may also use a portion of the net proceeds for the investment in strategic
partnerships and possibly the acquisition of complementary businesses, products, and/or technologies, although we have no present commitments
or agreements for any specific acquisitions or investments.
DETERMINATION
OF OFFERING PRICE
The
offering price of the Shares has been arbitrarily determined and bears no relationship to any objective criterion of value. The price
does not bear any relationship to our assets, book value, any historical earnings or net worth. In determining the offering price, management
considered such factors as the prospects, if any, for similar companies, anticipated results of operations, present financial resources,
and the likelihood of acceptance of this offering. In addition, no investment banker, appraiser, or other independent third party has
been consulted concerning the offering price for the Shares or the fairness of the offering price used for the Shares. We cannot assure
you that a public market for our securities will develop or continue or that the securities will ever trade at a price higher than the
offering price.
CORPORATE
HISTORY
The
Company
The
Company was incorporated in the State of Nevada in February 2007 as Aventerra Exploration, Inc. The Company amended its Articles of Incorporation
to change its name to AM Oil Resources & Technology, Inc. in December 2008. The Company merged with Medical Care Technologies, Inc.
and changed its name to Medical Care Technologies, Inc. in October 2009.
From
2016 to 2021 the Company failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting
of stockholders and pay its annual franchise tax resulting in its Nevada charter being revoked. On May 13, 2021, a shareholder filed
a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company on May 28,
2021. The Company’s Nevada charter was reinstated on June 4, 2021, and all required reports were filed with the State of Nevada
soon after.
On
October 3, 2022, Krisa Management LLC sold the Special 2021 Series A Preferred share to Marshall Perkins. The Company then acquired Infinite
Auctions LLC.
Our
principal executive office is located at 530 E. Hunt Hwy. Suite 103-225 San Tan Valley,
AZ. 85143, Email: info@infiniteauctions.com, Tel: 480-988-5847
The
Company is in the development stage and faces all of the risks and uncertainties associated with a new and unproven business. Our future
is based on an unproven business plan with no historical facts to support projections and assumptions. While the Company currently generates
revenues there can be no assurance that the Company will ever achieve profitability.
DESCRIPTION
OF BUSINESS
Company
Overview
Infinite
Auctions is an online auction house that provides an online platform for memorabilia collectors and professional athletes to consign
and sell high valued collectibles in a secure online auction format. Since 2016 we have sold more than $13.5 million in sports collectibles.
We currently specialize in the auctioning of game worn sports memorabilia that includes jerseys, helmets, bats and other items worn or
used by athletes in professional sporting events. We also auction high-end sports cards, trading cards, fine autographs, Americana and
other valuable antiquities. Our auction service gives collectors of high value memorabilia a safe environment to sell their collectibles
where the prices are substantially higher than you would see on mainstream online auction sites like Ebay and much safer than meeting
a potential buyer on the street with a bag of cash or facing the risk of digital payment return fraud. In addition to our regular online
auction services, our private sale brokering program connects sellers and buyers outside of auction for quicker sales. We often set records
with our private sales as we recently sold a Tom Brady game worn jersey for a record $500,000. We also actively make purchases both privately
and through public auctions for later resale as the collectibles industry continues to be in a considerable appreciation cycle over the
last several decades.
Industry
Overview
The
Seton Hall Sports Poll reported 28% of US households actively collect sports memorabilia.[1] Heritage Auctions, one of the
leading auction houses in the industry, had gross sales just over a billion dollars in 2023. Infinite Auctions is one of around 25 sports
memorabilia auction houses that all range in size and the types of collectibles that they specialize in. Over
[1]
https://www.thesetonian.com/article/2024/05/sports-memorabilia-and-collecting
the last decade, sports
collectibles have significantly increased in value, bringing in a whole new class of collectors.
The
market's growth is underpinned by both the emotional value that fans place on owning a piece of their favorite sports’ history
and the financial value as many items appreciate over time. Additionally, the advent of digital platforms and blockchain technology has
expanded the scope of what can be collected, now including digital collectibles and NFTs.
Market
Segments
The
sports memorabilia market is typically segmented based on the type of items, sports type, and distribution channel:
Type
of Items:
| • | Autographed
Memorabilia: This includes signed jerseys, balls, photographs, and other equipment. These
are highly sought after due to their authenticity and connection to sports icons. |
| • | Trading
Cards: Cards, especially those featuring prominent athletes, are immensely popular, with
some rare editions fetching millions of dollars at auctions. |
| • | Apparel
and Equipment: Jerseys, helmets, gloves, and bats, either used in games or replicas, form
a substantial part of the market. |
| • | Digital
Memorabilia: With the rise of digital technology, virtual items like NFTs associated with
memorable sports moments or digital autographs are gaining traction. |
Sports:
Different
sports have varying levels of collectible trading activity, with the most prominent being baseball, basketball, football, and soccer.
Each sport has its unique set of collectibles, with baseball historically being the leader in the memorabilia market.
Distribution
Channels:
| • | Online
Retail: Online platforms are the fastest-growing distribution channel, providing a global
reach and ease of access to rare items. |
| • | Auctions:
High-value collectibles are often sold at auctions. In addition to auction houses with a
specific focus on memorabilia, notable auction houses like Sotheby’s and Christie’s
regularly feature sports memorabilia. |
| • | Retail
Stores and Specialty Shops: These are traditional venues where collectors can purchase memorabilia,
although their prominence is slightly decreasing due to the rise of online sales. |
Market
Trends and Drivers
| • | Technological
Advancements: The integration of technologies like blockchain for verifying authenticity
and provenance of memorabilia items has been a key driver. Digital collectibles and NFTs
are expanding the market to include digital-native consumers. |
| • | Celebrity
and Historical Significance: Items associated with legendary figures or monumental sports
events command premium prices and have a dedicated collector base. |
| • | Media
and Entertainment: Documentaries and movies about sports stars or iconic sports moments can
spike interest and value in related memorabilia. |
| • | Globalization
of Sports: Increased global interest in leagues like the NBA, NFL, and English Premier League
has widened the market base, bringing in international buyers and sellers. |
| • | COVID-19
Impact: The pandemic initially disrupted the market, especially live auction events and physical
retail channels. However, it also boosted online sales and digital collectibles due to increased
online engagement. |
Our
Services and Sales Structure
Sellers
are charged a fee of up to 20% of the final bid to sell their consigned items in our auctions all while the buyers of each item are also
charged a 20% buyer’s premium. This standard consignment agreement setup results in a max profit of up to 40% of the value of each
item sold in auction. However, for ultra-premium consignments and sports cards the seller fee of 20% may be discounted or waived all
together and a portion of the buyer’s premium may also be awarded to the seller. The resulting profit range for consigned items
is a maximum of 40% and a minimum of 7% depending on the consignment agreement.
Auction
Schedule, Number Of Auctions, Auction Revenue
At
Infinite Auctions, annually, we conduct three to four large auctions, complemented by approximately two to three flash auctions and charity
auction events during the year. These auctions have showcased a wide range of collectibles and memorabilia, with sales reaching up to
$850,000. While we schedule our larger main auctions almost quarterly, our approach remains adaptable rather than rigidly bound by timeframes.
Occasionally, when presented with consignments of larger collections, we may opt to host separate auctions outside of our regular schedule
or adjust our auction calendar accordingly. Ultimately, our decision-making process revolves around the flow of consignments, ensuring
that we can consistently deliver exceptional auctions that meet the diverse needs and expectations of our valued clientele.
We
utilize the SimpleAuctionSite Software for our auction platform. This software is a familiar and trusted choice within the sports auction
industry, known for its reliability and ease of use. Widely adopted by high-end bidders in the collectibles space, SimpleAuctionSite
offers a user-friendly experience, making it seamless for both buyers and sellers to navigate auctions and place bids with confidence.
With its robust features and widespread recognition, SimpleAuctionSite enhances the overall auction experience, ensuring smooth transactions
and satisfaction for all participants.
Marketing
Strategy
We
use a number of digital marketing resources that include the services of auction report, press releases Facebook/Instagram digital marketing,
Google digital marketing, all combined with our email list of almost 17,000 memorabilia collectors. We have moved away from print advertising
as it has proven to be less cost efficient and effective as our digital advertising approach. The average total cost of marketing per
auction is approximately $10,000 - $20,000.
Employees
Marshall
Perkins is the sole full time employee of the company. Other needed services such as photo editing, auction writing, graphic design,
and marketing are outsourced through. As cash flow increases the company intends to hire a full-time consignment director.
Competition
Goldin
Auctions is the most prominent auction house that has a sole focus on sports cards, trading cards, game used memorabilia and now video
games. They grossed $100 million in total sales in 2020. Goldin Auctions had over $400 million in gross sales in 2023. Heritage Auctions
is an industry leader in the online auction realm but sells much more than sports
memorabilia as their scope ranges from fine wine to
antique artifacts and coins. Further, Heritage Auctions grossed over $1 billion in 2023.
Goldin
and Heritage both have a dozen or more consignment directors as well as physical locations that must be maintained. Infinite Auctions
will be moving into a monthly auction format in 2025 which will help us turn inventory faster for greater annual gains all while getting
our consignors faster payouts. One advantage that we have on our competition is our low overhead expenses, the fact that consignors and
bidders have direct access to the owner of the company and we offer a wealth of hands on guidance when it comes to memorabilia authentication
that other auction houses don’t always offer.
Ebay
has solidified its position as a formidable player in the sports collectibles space, standing out for its competitiveness and expansive
offerings. With a vast network of sellers and buyers worldwide, Ebay provides a diverse marketplace where enthusiasts can discover a
wide range of sports memorabilia, from vintage baseball cards to autographed jerseys of their favorite athletes. The platform's auction
format fosters a dynamic environment that encourages competitive bidding, driving prices and excitement among collectors. Additionally,
Ebay's user-friendly interface and robust search functionality make it easy for collectors to find rare and unique items, further enhancing
its appeal in the sports collectibles market. Overall, Ebay continues to thrive as a premier destination for sports enthusiasts seeking
to expand their collections or sell prized memorabilia.
Steiner
Sports has established itself as a key player in the competitive sports autographs and collectibles market. Renowned for its authenticity
and extensive selection, Steiner offers a wide array of signed memorabilia, ranging from iconic jerseys to rare photographs, catering
to enthusiasts and collectors alike. With partnerships with top athletes and exclusive access to memorable sports moments, Steiner delivers
unique and sought-after items that captivate fans worldwide. Moreover, their commitment to authenticity and customer satisfaction sets
them apart, ensuring that every piece of memorabilia meets the highest standards. As a result, Steiner Sports remains a dominant force
in the sports autographs and collectibles space, continuously delivering unparalleled experiences for sports enthusiasts.
Near
Term Growth Strategy
We
are focusing our efforts on increasing buyer and seller engagement by increasing the number of auctions that we run each year and by
also introducing a stronger marketing plan and hiring consignment directors to assist in acquiring consignments. We are seeking to add
a mobile app to have a sleeker and more futuristic feel for our clients all while keeping the engagement process as simple as possible.
We are placing an extreme focus on increasing our inventory catalog as it will drive revenue and attract consignors of high value memorabilia
which also helps the company’s bottom line as we acquire more consignments for auction, and private sales. In the past we have
used a cookie cutter approach to advertising, but moving forward we are looking forward to using mass marketing tools such as nationwide
television and radio advertising along with our traditional digital marketing strategies.
Long
Term Growth Strategy
Ultimately
the name "Infinite Auctions” was chosen because there are infinite possibilities when it comes to what we can auction on our
platform with our array of potential collector clients. In the future we plan on breaking into other markets, which will include comic
books, graded video games, high end time pieces, art and much more. The comic book industry alone sold $1.28 billion in 2023 as prices
began to emerge. The used watch market is estimated to be in the hundreds of millions in 2023 as well. In order to fully scale our business
to compete with the heads of the collectibles industry we would need to hire additional staff that would include consignment directors
to assist in acquiring consignments and a digital marketing specialist that would keep us relevant in the eyes of our potential and existing
clients with consistent and creative marketing efforts. Further, in order to truly maximize the company's potential, we would need an
increased travel budget in order to attend the top national sports conventions each year that could dramatically increase our revenue.
In addition, we are looking to possible acquire other auction sites and memorabilia dealers.
Government
Regulation
Online
auctions in the United States are primarily regulated under the same legal frameworks that govern traditional auctions, but with additional
considerations specific to the digital nature of the transactions. However, many states do not require licenses for online auctions as
they would for more traditional auctions. Here are the key aspects of U.S. regulations that pertain to online auctions:
1.
Federal Trade Commission (FTC): The FTC plays a central role in regulating online auctions. It enforces laws that protect consumers from
deceptive and unfair business practices. For instance, auction sites are required to provide clear information about the products being
sold, terms of the sale, and the bidding process. Additionally, the FTC's Mail, Internet, or Telephone Order Merchandise Rule mandates
that sellers ship items within the time stated or within 30 days if no specific time is promised.
2.
Uniform Commercial Code (UCC): The UCC, which has been adopted in some form by all U.S. states, applies to transactions involving the
sale of goods, including online auctions. It outlines the rights and obligations of both buyers and sellers in auction transactions.
3.
State Laws: Each state may have additional laws and regulations that impact online auctions. These might include specific requirements
for licenses, taxes, or additional consumer protections that go beyond federal regulations.
4.
Consumer Protection Laws: Apart from the FTC, state attorney generals can enforce local consumer protection laws. These laws help ensure
that auction sites operate transparently and fairly, and they help in prosecuting cases of fraud or misrepresentation.
5.
Online Payment Regulation: Financial transactions in online auctions are subject to regulations concerning electronic payments. Laws
such as the Electronic Fund Transfer Act (EFTA) protect consumers when they transfer funds electronically, including via credit cards,
debit cards, and electronic checks.
6.
Data Privacy and Security: Online auction sites must comply with federal and state data privacy and security laws. These include regulations
about how consumer information is collected, stored, and shared. The Children’s Online Privacy Protection Act (COPPA) is particularly
significant if the site collects information from children under the age of 13.
7.
Accessibility: Online auction platforms must also adhere to regulations concerning accessibility. For example, the Americans with Disabilities
Act (ADA) may require that online auction sites be accessible to individuals with disabilities.
8.
Intellectual Property: Online auctions must ensure they do not facilitate the sale of counterfeit goods, which would infringe on intellectual
property rights. Enforcement here often involves cooperation with intellectual property rights holders and compliance with both U.S.
and international laws regarding intellectual property.
9.
Anti-Money Laundering Laws: Online auction platforms must also be aware of AML regulations, which aim to prevent the laundering of money
through auction transactions. Compliance includes conducting due diligence on high-value bidders and reporting suspicious activities
to the authorities.
LEGAL
PROCEEDINGS
From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However,
litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm our business. We are currently not aware of any such legal proceedings or claims against the Company.
DILUTION
Purchasers
of our Shares offered in this Offering Circular will experience an immediate and substantial dilution of the net tangible book value
of their Shares from the initial public offering price. Net tangible book value per share of our common stock before this offering is
determined by dividing net tangible book value based on March 31, 2024, net book value of the tangible assets (consisting of total assets
less intangible assets) of the Company by the number of shares of our common stock issued. The table below is based upon the Company
completing the offering at the lowest price in the offering range.
Assumed
initial public offering price per share |
|
$ |
.0005 |
|
Net
tangible book value per share before this offering |
|
$ |
.00036 |
|
Increase
in pro forma net tangible book value per share attributable to this offering (1) |
|
$ |
0.00004 |
|
Expenses
impacting net tangible book value per share after this offering |
|
$ |
50,000 |
|
Pro
forma net tangible book value per share after this offering |
|
$ |
0.00041 |
|
Dilution
in pro forma net tangible book value per share to new investors (Purchase Price of $0.0005 Less Pro Forma Net Tangible Book Value
Per Share) |
|
$ |
(0.00009) |
|
(1)
The increase in pro forma net tangible book value per share attributable to this offering is determined by subtracting (a) the sum of
(i) the pro forma net tangible book value per share before this offering (see note above) and (ii) the decrease in pro forma net tangible
book value per share divided by (ii) the number of outstanding shares of common stock after this offering.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
following discussion and analysis of our results of operations and financial condition should be read in conjunction with our financial
statements and the notes to those financial statements that are included elsewhere in this document. Our discussion includes forward-looking
statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions.
Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result
of a number of factors.
Results
of Operations for the Years ended December 31, 2023 and 2022
Revenues
For
the years ended December 31, 2023 and 2022 we had revenues of $731,971 and $3,469,685, respectively. Gross profit decreased from $1,330,000
in 2022 to ($57,237) in 2023, mainly due to the rapid downturn in the sports collectibles market. This decline prompted us to sell off
our inventory at significantly lower prices than their original purchase prices, leading to substantial losses. Given the challenging
climate in the sports cards market, we made the strategic decision to liquidate all
sports cards from our inventory. While this decision
was necessary to adapt to the changing market dynamics, it resulted in a negative gross profit for the year.
Operating
Expenses
We
incurred $323,784 in operating expenses for the year ended December 31, 2023, as compared with $230,895 during the year ended December
31, 2022. The increase in operating expenses is the result of higher expenses in areas such as marketing, and professional services such
as legal and accounting during the year ended December 31, 2023. We expect our operating expenses will continue to increase in future
years as a result of the costs associated with the increased operating activity under our business model.
Other
Income/Expenses
We
had interest expenses of $6,485 for the year ended December 31, 2023 compared to $0 for the same period of 2022.
Net
Loss
We
recorded a net loss of $387,506 for the year ended December 31, 2023, compared to a net profit of $1,099,105 for the year ended December
31, 2022. The increase in the net loss is the result of the factors discussed above.
Results
of Operations for the Three months ended March 31, 2024 and 2023
Revenues
We
had revenues of $7,114 and $122,706 for three months ended December 31, 2024 and 2023. The decline in revenue is due to our previous
sell off inventory as the sports memorabilia began to decline.
Operating
Expenses
We
incurred $ 33,710 in operating expenses for the three months ended March 31, 2024, as compared with $64,963 during the three months
ended March 31, 2023. We expect our operating expenses will continue to increase in future years as a result of the costs associated
with the increased operating activity under our business model.
Other
Income/Expenses
We
had interest expenses of $1,965 for the three months ended March 31, 2024 compared to $1,675 for the same period of 2022.
Net
Loss
For
the three months ended March 31, 2024 and March 31, 2024 we had a net loss of $34,552 and $226,977. This decrease was due to lower sales
and lower costs of sales during the most recent period.
Liquidity
and Capital Resources
Our
financing objective is to maintain financial flexibility to meet the material, equipment and personnel needs to support our project commitments,
and pursue our expansion and diversification objectives.
As
of March 31, 2024, we had total current assets of $1,298,026 and total current liabilities of $98,598.
Net
cash used by operating activities was $708,268 for the three months ended March 31, 2024, as compared with net cash provided by operating
activities of $19,931. This includes 706,288 used to purchase inventory during the most recent quarter
Net
cash provided by operating activities was $29,912 for the year ended December 31, 2023, as compared with $139,548 in cash provided for
the year ended December 31, 2022.
Financing
activities provided $6,321 in cash for the year ended December 31, 2023, as compared with $127,750 for the year ended December 31, 2022.
PLAN
OF DISTRIBUTION
The
Company is offering a maximum of $1,000,000 in Shares of its Common Stock on a best-efforts basis at a fixed price of $[ ] per share
and any funds raised from this Offering will be immediately available to the Company. The Offering will terminate upon the earlier of
the sale of all the Shares or one year from the date of this Offering Statement.
There
is no aggregate minimum to be raised in order for subscription proceeds to be released to the Company and therefore the Offering will
be conducted on a “rolling basis.” This means we are entitled to begin applying “dollar one” of the proceeds
from the Offering towards our business strategy, including, without limitation, research and development expenses, offering expenses,
working capital, general corporate purposes, repayment of debt (if any) and, prior to our use of the proceeds, other uses, including
short-term, interest-bearing investments, as more specifically set forth in the “Use of Proceeds” starting on page 17.
The
Offering may be made, in management’s discretion, directly to investors by the Company’s management on a “best efforts”
basis. We reserve the right to offer the Shares through broker-dealers who are registered with FINRA/SIPC. The Company may engage a broker-dealer
registered with the SEC and a member of FINRA/SIPC to perform administrative compliance and related broker-dealer services in connection
with this Offering including the review of investor information including KYC (Know Your Customer) data, AML (Anti-Money Laundering)
and other compliance checks and review of subscription agreements and investor information. Rule 3a4-1 provides an exemption from the
broker-dealer registration requirements of the Exchange Act for persons associated with an issuer that participate in an offering of
the issuer’s securities. None of our officers or directors are subject to any statutory disqualification, as that term is defined
in Section 3(a)(39) of the Exchange Act. Our officers or directors will not participate in selling an offering of securities for any
issuer more than once every 12 months other than in reliance on Exchange Act Rule 3a4-1(a)(4)(i) or (iii) except that for securities
issued pursuant to rule 415 under the Securities Act, the 12 months shall begin with the last sale of any security included within one
rule 415 registration.
We
intend to sell the Shares in this offering through our Board of Directors and their affiliates. They will not receive any compensation
for offering or selling the Shares. We reserve the right to reject, in whole or in part, any subscriptions for Shares made in this Offering,
in our discretion.
Selling
Agents and Expenses
We
may engage broker-dealers registered under Section 15 of the Exchange Act (“Selling Agents”), and who are FINRA members
to participate in the offer and sale of the Shares and to pay to such persons, if any, cash commissions of up to 10% of the gross proceeds
from the sales of Shares placed by such persons and agent warrants (“Agent Shares”) to purchase that number of Shares
equal to 10% of the Shares placed by such persons.
We
have not entered into selling agreements with any broker-dealers to date. We will be responsible for and pay all expenses relating to
this Offering, including, without limitation, (a) all filing fees and expenses relating to the qualification of this Offering with the
SEC and the filing of the offering materials with FINRA, as applicable; (b) all fees and expenses relating to the registration or qualification
of the Shares as required under State Blue Sky laws, including the fees of counsel selected by us; (c) the costs of all preparing and
printing of the offering documents; (d) the costs of preparing, printing and delivering certificates representing Shares; (e) fees and
expenses of the transfer agent for the Shares; and (f) the fees and expenses of
our accountants and the fees and expenses of our legal
counsel and other agents and representatives. We expect the total expenses to be paid by us will be at least $50,000.
Offering
Period
We
expect to commence the sale of the Shares within two days following the Qualification Date. This Offering will terminate on the Termination
Date.
Offering
Documents
This
Offering Statement and the offering documents specific to this Offering will be available to prospective investors for viewing 24 hours
per day, 7 days per week on our website at www.infinteauctions.com. Before committing to purchase Shares, each potential investor must
consent to receive the final Offering Statement and all other offering documents electronically. In order to purchase Shares, a prospective
investor must complete and sign and deliver to us a Subscription Agreement, the form of which is an exhibit to the Offering Statement
of which this Offering Statement is a part and send payment to us as described in the Subscription Agreement. Prospective investors must
also have agreed to the Terms of Use and Privacy Policy of our website.
Prospective
investors must read and rely on the information provided in this Offering Statement in connection with any decision to invest in the
Shares. For general information on investing, we encourage you to refer to www.investor.gov.
State
Blue Sky Information
If
we fail to comply with State securities laws where our securities are sold, we may be subject to fines and other regulatory actions against
us. We intend to take the steps necessary to help insure that offers and sales in this Offering are in compliance with State Blue Sky
laws, provided, however, there can be no assurance that we will be able to achieve such compliance in all instances, or avoid fines or
other regulatory actions if we are not in compliance.
DIRECTORS
AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Biographical
information regarding the officers and directors of the Company, who will continue to serve as officers and Directors of the Company
are provided below:
Officer
Biographies
NAME |
AGE |
POSITION |
Marshall
Perkins III |
43 |
Chief
Executive Officer, President, Secretary, Treasurer, Director |
Management
Biographies
Marshall
Perkins
Marshall
Perkins has been the CEO Infinite Auctions since 2016. Within this position, he has had diverse responsibilities ranging from auctioneer
to consignment director, lead photographer, auction writer, and marketing director.
A
foremost expert in game used memorabilia with a 12-year history as a pioneer in sports memorabilia authentication and sales with more
than 30 years of experience in the arena. Marshall Perkins has worked with both the top collectors and high profile professional athletes
and is known across the game used sports memorabilia industry for introducing some of the most important and historic memorabilia to
light using an iron clad method of authentication called photo matching. Marshall was responsible for introducing items such as Mickey
Mantle’s 1960 NY Yankees World Series jersey to the industry as well as
Michael Jordan’s 1985-86 Chicago Bulls uniform from
his very first NBA Slam Dunk Contest Title. Marshall has been an asset to the collectibles industry and will continue to be an asset
to the consignors and bidders at Infinite Auctions.
Corporate
Governance
The
Company promotes accountability for adherence to honest and ethical conduct; endeavors to provide full, fair, accurate, timely and understandable
disclosure in reports and documents that the Company files with the Securities and Exchange Commission (the “SEC”) and in
other public communications made by the Company; and strives to be compliant with applicable governmental laws, rules, and regulations.
The Company has not formally adopted a written code of business conduct and ethics that governs the Company’s employees, officers
and Directors as the Company is not required to do so.
In
lieu of an Audit Committee, the Company’s Board of Directors, is responsible for reviewing and making recommendations concerning
the selection of outside auditors, reviewing the scope, results, and effectiveness of the annual audit of the Company's financial statements
and other services provided by the Company’s independent public accountants. The Board of Directors, the Chief Executive Officer
and the Chief Financial Officer of the Company review the Company's internal accounting controls, practices, and policies.
Committees
of the Board
Our
Company currently does not have nominating, compensation, or audit committees or committees performing similar functions nor does our
Company have a written nominating, compensation, or audit committee charter.
Involvement
in Certain Legal Proceedings
Our
Director and our Executive Officer has not been involved in any of the following events during the past ten years:
| 1. | bankruptcy
petition filed by or against any business of which such person was a general partner or executive
officer either at the time of the bankruptcy or within two years prior to that time; |
| 2. | any
conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding
traffic violations and other minor offenses); |
| 3. | being
subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending
or otherwise limiting his involvement in any type of business, securities or banking activities;
or |
| 4. | being
found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity
Futures Trading Commission to have violated a federal or state securities or commodities
law, and the judgment has not been reversed, suspended, or vacated. |
| 5. | Such
person was found by a court of competent jurisdiction in a civil action or by the Commission
to have violated any Federal or State securities law, and the judgment in such civil action
or finding by the Commission has not been subsequently reversed, suspended, or vacated; |
| 6. | Such
person was found by a court of competent jurisdiction in a civil action or by the Commodity
Futures Trading Commission to have violated any Federal commodities law, and the judgment
in such civil action or finding by the Commodity Futures Trading Commission has not been
subsequently reversed, suspended or vacated; |
| 7. | Such
person was the subject of, or a party to, any Federal or State judicial or administrative
order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating
to an alleged violation of: (i) Any Federal or State securities or commodities law or regulation;
or (ii) Any law or regulation respecting financial institutions or insurance companies including,
but not limited to, a temporary or permanent injunction, order of disgorgement or restitution,
civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition
order; or (iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection
with any business entity; or |
| 8. | Such
person was the subject of, or a party to, any sanction or order, not subsequently reversed,
suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26)
of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section
1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange,
association, entity or organization that has disciplinary authority over its members or persons
associated with a member. |
Code
of Ethics
We
have not adopted a formal Code of Ethics. The Board of Directors evaluated the business of the Company and the number of employees and
determined that since the business is operated by a small number of persons, general rules of fiduciary duty and federal and state criminal,
business conduct and securities laws are adequate ethical guidelines. In the event our operations, employees and/or Directors expand
in the future, we may take actions to adopt a formal Code of Ethics.
Shareholder
Proposals
Our
Company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for Directors.
The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature and of little
assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum
criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such
nominees. The Board of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations
for election or appointment.
A
shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our President,
at the address appearing on the first page of this Information Statement.
SECURITY
OWNERSHIP
The
following table sets forth certain information as of March 31, 2024, with respect to the holdings of: (1) each person known to us to
be the beneficial owner of more than 5% of our Common Shares; (2) each of our directors, nominees for director and named executive officers;
and (3) all directors and executive officers as a group. To the best of our knowledge, each of the persons named in the table below as
beneficially owning the Shares set forth therein has sole voting power and sole investment power with respect to such Shares, unless
otherwise indicated. Unless otherwise specified, the address of each of the persons set forth below is in care of the Company. The percentages
are based on 3,209,575,220 Shares of our Common Stock outstanding as of the date above.
Name
|
Common
Stock |
% Before
Offering(1) |
% After
Offering |
Series A
Preferred Stock |
Marshall
Perkins III (1) |
1,980,000,000 |
61.69% |
[
]% |
1 |
All Executive
Officers As A Group |
1,980,000,000 |
61.69% |
[
]% |
1 |
5%
Owners |
|
|
|
|
Carey
W. Cooley |
170,000,000 |
5.30% |
[ ]% |
- |
Quartermaine
Asquith & Associates Ltd (2) |
200,000,000 |
6.23% |
[ ]% |
- |
(1) The
address for Marshall Perkins III is care of the Company at 530 E. Hunt Hwy. Suite 103-225 San Tan Valley, AZ. 85143
(2) F.
James Nelson is the beneficial owner of Quartermaine Asquith & Associates Ltd.,
a Hong Kong Company.
Regardless
of the success of this offering, our officers and director and current stockholders will continue to own the majority of our Shares after
the offering. Since they may continue to control the Company after the offering, investors may be unable to change the course of the
operations. Thus, the Shares we are offering may lack the value normally attributable to voting rights. This could result in a reduction
in value of the Shares you own because of their ineffective voting power. None of our Shares is subject to outstanding options, warrants,
or securities convertible into Shares.
The
Company’s voting securities consist of Common Shares and Preferred Stock. Beneficial ownership is determined in accordance with
SEC rules and generally includes sole or shared voting or investment power with respect to voting securities. For purposes of this table,
a person or group of persons is deemed to have “beneficial ownership” of any voting securities that such person or any member
of such group has the right to acquire within 60 days of the date of this Offering Statement. For purposes of computing the percentage
of the Company’s outstanding voting securities held by each person or group of persons named above, any securities that such person
or persons has the right to acquire within 60 days of the date of this Offering Statement are deemed to be outstanding for such person,
but not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. Beneficial ownership as determined
under SEC rules is not necessarily indicative of beneficial or other ownership for any other purpose. The inclusion herein of any securities
listed as beneficially owned does not constitute an admission of beneficial ownership by any person.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Other
than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own
beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons
or companies, has any material interest, direct or indirect, in any transaction that has occurred during the past fiscal year, or in
any proposed transaction, which has materially affected or will affect the Company.
With
regard to any future related party transaction, the Company plans to fully disclose any and all related party transactions in the following
manner:
|
• |
Disclosing such transactions
in reports where required; |
|
• |
Disclosing in any and all
filings with the SEC, where required; |
|
• |
Obtaining disinterested
director’s consent; and |
|
• |
Obtaining shareholder consent
where required. |
Review,
Approval or Ratification of Transactions with Related Persons
The
Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide
the information under this item. Given our small size and limited financial resources, we have not adopted formal policies and procedures
for the review, approval, or ratification of transactions, such as those described above, with our executive officers, Directors, and
significant stockholders. We intend to establish formal policies and procedures in the future, once we have sufficient resources and
have appointed additional Directors, so that such transactions will be subject to the review, approval or ratification of our Board of
Directors, or an appropriate committee thereof. On a moving forward basis, our Directors will continue to approve any related party transaction.
EXECUTIVE
COMPENSATION
For
the fiscal years ended July 31, 2023 and 2022, we compensated our three highest-paid directors and executive officers as follows:
Name and principal position | |
Year Ended | |
Salary | |
Bonus | |
Stock Compensation | |
Option Awards | |
Non-Equity Incentive Plan Compensation | |
Nonqualified Deferred Compensation Earnings | |
Total |
(a) | |
(b) | |
($) (c) | |
($) (d) | |
($) (e) | |
($) (f) | |
($) (g) | |
($) (h) | |
($) (j) |
Marshall Perkins III | |
| 2023 | | |
| 20,916 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 20,916 | |
CEO (1) | |
| 2022 | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
Summary
of Compensation
Stock
Option Grants
We
have not granted any stock options to our executive officer since our incorporation.
Employment
Agreements
We
do not have any employment agreements.
Director
Compensation
Our
Board of Directors does not currently receive any consideration for their services as members of the Board of Directors. The Board of
Directors reserves the right in the future to award the members of the Board of Directors cash or stock-based consideration for their
services to the Company, which awards, if granted shall be in the sole determination of the Board of Directors.
Executive
Compensation Philosophy
Our
Board of Directors determines the compensation given to our executive officers in their sole determination. Our Board of Directors reserves
the right to pay our executives or any future executives a salary, and/or issue them shares of common stock issued in consideration for
services rendered and/or to award incentive bonuses which are linked to our performance, as well as to the individual executive officer’s
performance. This package may also include long- term stock-based compensation to certain executives, which is intended to align the
performance of our executives with our long-term business strategies. Additionally, while our Board of Directors has not granted any
performance base stock options to date, the Board of Directors reserves the right to grant such options in the future, if the Board in
its sole determination believes such grants would be in the best interests of the Company.
Incentive
Bonus
The
Board of Directors may grant incentive bonuses to our executive officer and/or future executive officers in its sole discretion, if the
Board of Directors believes such bonuses are in the Company’s best interest, after analyzing our current business objectives and
growth, if any, and the amount of revenue we are able to generate each month, which revenue is a direct result of the actions and ability
of such executives.
Long-term,
Stock Based Compensation
In
order to attract, retain and motivate executive talent necessary to support the Company’s long-term business strategy we may award
our executives and any future executives with long-term, stock-based compensation in the future, at the sole discretion of our Board
of Directors, which we do not currently have any immediate plans to award.
Transactions
with Related Persons, Promoters, Certain Control Persons & Director Independence
Other
than the issuance of shares to our current Sole-Officer, we do not have any transactions with related persons to report.
Changes
in and Disagreements with Accountants
on
Accounting
& Financial Disclosure
There
have not been any changes in or disagreements with accountants on accounting and financial disclosure or any other matter.
Interests
of Named Experts and Counsel
No
expert or counsel named in this Offering Circular as having prepared or certified any part of this Offering Circular or having given
an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering
of the Common Shares was employed on a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest,
direct or indirect, in the registrant or any of its parents or subsidiaries. Nor was any such person connected with the registrant or
any of its parents or subsidiaries as a promoter, managing or principal underwriter, voting trustee, director, officer, or employee.
Jonathan
D. Leinwand, P.A., will pass on the validity of the Shares being offered pursuant to this Offering Circular.
DESCRIPTION
OF SHARES
The
Company has 7,979,999,990 (Seven Billion Nine Hundred Seventy-Nine Million-Nine Hundred Ninety-Nine Thousand-Nine Hundred Ninety) authorized
common shares and 20,000,0010 (Twenty Million and Ten) authorized preferred shares of which 1 (One) preferred Share is designated as
Special 2021 Series A Preferred Stock. 3,209,575,220 shares of common stock and 1 share of Special 2021 Series A preferred stock are
issued and outstanding.
Common
Stock
The
holders of outstanding shares of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment
of dividends of such times and in such amounts as the board from time to time may determine. Holders of Common Stock are entitled to
one vote for each share held on all matters submitted to a vote of shareholders. There is no cumulative voting of the election of directors
then standing for election. The Common Stock is not entitled to pre-emptive rights and is not subject to conversion or redemption. Upon
liquidation, dissolution or winding up of our Company, the assets legally available for distribution to stockholders are distributable
ratably among the holders of the Common Stock after payment of liquidation preferences, if any, on any outstanding payment of other claims
of creditors.
Preferred
Stock
Special
2021 Series A Preferred Stock
The
following describes the material terms of the Special 2021 Series A Preferred. This is not a complete description and is subject to,
and entirely qualified by reference to applicable provisions of our Articles of Incorporation, Bylaws and the Certificate of
Designation establishing the Special 2021 Series A Preferred Stock, which are filed as exhibits to this Offering Statement.
Capitalized terms used but not defined in this subsection shall have the meanings ascribed to them in the Certificate of Designation
establishing the Special 2021 Series A Preferred Stock
Voting
The
2021 Series A Preferred Stock stockholder is entitled to 60% of all votes (including, but not limited to, common stock, and
preferred stock (including on an as converted basis) entitled to vote at each meeting of stockholders of the Corporation (and
written actions of stockholders in lieu of meetings) with respect to any and all matters presented to the stockholders of the
Corporation for their action or consideration.
Conversion
into Common Stock
The
share of 2021 Series A Preferred Stock is convertible into common shares at a conversion rate of 1 preferred to 3,000,000,000 (Three
Billion) common shares. The holder of the 2021 Series A Preferred Stock can affect the conversion at any time.
Dividends,
Liquidation.
The
share of 2021 Series A Preferred Stock shall not be entitled to any dividends in respect thereof, and shall not participate in any proceeds
available to the Corporation’s shareholders upon the liquidation, dissolution or winding up of the Corporation.
There
are no redemption rights or sinking fund provisions.
Dividend
Policy
We
have not paid any cash dividends to shareholders. The declaration of any future cash dividends is at the discretion of our board of directors
and depends upon our earnings, if any, our capital requirements and financial position, general economic conditions, and other pertinent
conditions. It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest earnings, if
any, in our business operations.
Penny
Stock Regulation
The
SEC has adopted regulations which generally define “penny stock” to be any equity security that has a market price (as defined)
of less than $5.00 per share or an exercise price of less than $5.00 per share. Such securities are subject to rules that impose additional
sales practice requirements on broker-dealers who sell them. For transactions covered by these rules, the broker-dealer must make a special
suitability determination for the purchaser of such securities and have received the purchaser’s written consent to the transaction
prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the rules require the delivery, prior
to the transaction, of a disclosure schedule prepared by the SEC relating to the penny stock market. The broker-dealer also must disclose
the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the
broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over
the market. Finally, among other requirements, monthly statements must be sent disclosing recent price information for the penny stock
held in the account and information on the limited market in penny stocks. As the Shares immediately following this Offering will likely
be subject to such penny stock rules, purchasers in this Offering will in all likelihood find it more difficult to sell their Shares
in the secondary market.
Indemnification
The
Corporation shall indemnify, to the fullest extent permitted by applicable law, any person, and the estate and personal representative
of any such person, against all liability and expense (including attorneys’ fees) incurred by reason of the fact that he is or
was a director or officer of the Corporation or, while serving at the request of the Corporation as a director, officer, partner, trustee,
employee, fiduciary, or agent of, or in any similar managerial or fiduciary position of, another domestic or foreign corporation or other
individual or entity or of an employee benefit plan. The Corporation also shall indemnify any person who is serving or has served the
Corporation as director, officer, employee, fiduciary, or agent, and that person’s estate and personal representative, to the extent
and in the manner provided in any by law, resolution of the shareholders or directors, contract, or otherwise, so long as such provision
is legally permissible.
Limitation
of Director Liability
Nevada
law currently provides that our directors will not be personally liable to our Company or our stockholders for monetary damages for any
act or omission as a director other than in the following circumstances:
|
• |
the director breaches his
fiduciary duty to our Company, or our stockholders and this breach involves intentional misconduct, fraud, or a knowing violation
of law; or |
|
• |
our Company makes an unlawful
payment of a dividend or unlawful stock purchases, redemptions, or other distributions. |
As
a result, neither we nor our stockholders have the right, through stockholders’ derivative suits on our behalf, to recover monetary
damages against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior,
except in the situations described above. Nevada law allows the articles of incorporation of a corporation to provide for greater liability
of the corporation’s directors. Our Articles of Incorporation do not provide for such expanded liability.
Any
repeal or modification of the foregoing paragraph by the shareholders of the Corporation shall not adversely affect any right or protection
of a director of the Corporation existing at the time of such repeal or modification.
Meetings
of Shareholders
Meetings
of shareholders shall be held at such time and place as provided in the Bylaws of the Corporation. At all meetings of the shareholders,
one-third of all votes entitled to be cast at the meeting shall constitute a quorum.
No
Cumulative Voting
There
shall be no cumulative voting for the election of directors.
Action
by Shareholders
Any
action required or permitted to be taken at a meeting of the shareholders may be taken without a meeting if a written consent (or counterparts
thereof) that sets forth the action so taken is signed by the shareholders having the minimum number of votes necessary to authorize
or take such action at a meeting at which all of the Shares entitled to vote thereon were present and voted.
SHARES
ELIGIBLE FOR FUTURE SALE
Prior
to this Offering, there has been a limited market for our Common Stock. Future sales of substantial amounts of our Common Stock, or securities
or instruments convertible into our Common Stock, in the public market, or the perception that such sales may occur, could adversely
affect the market price of our Common Stock prevailing from time to time. Furthermore, because there will be limits on the number of
shares available for resale shortly after this Offering due to contractual and legal restrictions described below, there may be resales
of substantial amounts of our Common Stock in the public market after those restrictions lapse. This could adversely affect the market
price of our Common Stock prevailing at that time.
Rule
144
In
general, a person who has beneficially owned restricted shares of our Common Stock for at least twelve months, in the event we are a
reporting company under Regulation A, or at least six months, in the event we have been a reporting company under the Exchange Act for
at least 90 days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate
of ours at the time of sale or to have been an affiliate of ours at any time during the 90 days preceding the sale. A person who is an
affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within any
three-month period only a number of shares that does not exceed the greater of the following:
|
• |
1% of the number of shares
of our Common Stock then outstanding; or |
|
• |
the average weekly trading
volume of our Common Stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect
to the sale; |
provided
that, in each case, we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule
144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.
Ability
to Void a Sale of Shares
We
have the right to void a sale of Shares in the Offering and compel an investor to return them to us, if we have reason to believe that
such investor acquired the Shares as a result of a misrepresentation, including with respect to such shareholder’s representation
that it is a “qualified purchaser” or an “accredited investor” as defined pursuant to Regulation A or Regulation
D promulgated under the Securities Act, respectively, or if the investor or the sale to the investor is otherwise in breach of the requirements
set forth in our Articles of incorporation, as amended, or bylaws, copies of which are exhibits to the Offering Statement in which this
Offering Statement has been filed with the SEC.
Rights
as a Stockholder
Except
as otherwise provided in the Shares or by virtue of such holder’s ownership of Shares of Common Shares, the holder of a Share does
not have the rights or privileges of a holder of Common Shares, including any voting rights.
Governing
Law
The
Shares are governed by and construed in accordance with the laws of the State of Nevada. The foregoing is a brief summary of certain
terms and conditions of the Shares to be issued in connection with this Offering and subject in all respects to the provisions contained
in the Shares.
No
Independent Counsel
Jonathan
D. Leinwand, P.A. (“Counsel”) represent the Company and its affiliates from time-to-time in a variety of matters. Counsel
does not represent any of the Investors in connection with the Company. Counsel represents the Company and its affiliates, including
with respect to the Company’s role in relation to the Company.
By
acquiring Shares in the Company, each Investor will be deemed to have waived any conflict and agreed that Counsel may act for the Company,
affiliates of the Company or any or all of them in matters adverse to such Investor and/or the Company.
TRANSFER
AGENT
The
transfer agent and registrar for our common stock is:
Manhattan
Transfer Registrar Co.
One
Grand Central Place
60
East 42nd Street, Suite 1201
New
York, NY 10165
LEGAL
MATTERS
Certain
legal matters with respect to the securities offered hereby will be passed upon by Jonathan D. Leinwand, P.A.
AVAILABLE
INFORMATION
We
have filed with the SEC an offering circular on Form 1-A under the Securities Act with respect to the Shares offered hereby. This offering
circular, which constitutes part of the offering circular, does not contain all of the information set forth in the offering circular
and the exhibits and schedule thereto, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For
further information regarding our Shares and our Company, please review the offering circular, including exhibits, schedules and reports
filed as a part thereof. Statements in this offering circular as to the contents of any contract or other document filed as an exhibit
to the offering circular, set forth the material terms of such contract or other document but are not necessarily complete, and in each
instance, reference is made to the copy of such document filed as an exhibit to the offering circular, each such statement being qualified
in all respects by such reference.
A
copy of the offering circular and the exhibits and schedules that were filed with the offering circular may be inspected without charge
at the Public Reference Room maintained by the Securities and Exchange Commission at 100 F Street, N.E. Washington, DC 20549, and copies
of all or any part of the offering circular may be obtained from the Securities and Exchange Commission upon payment of the prescribed
fee. Information regarding the operation of the Public Reference Room may be obtained by calling the Securities and Exchange Commission
at 1-800-SEC-0330. The Securities and Exchange Commission maintains a website that contains reports and other information regarding registrants
that file electronically with the SEC. The address of the website is www.sec.gov.
INDEX
TO FINANCIAL STATEMENTS
Unaudited
Financial Statements for the Three Months Ended March 31, 2024
Unaudited
Financial Statements for the Year Ended December 31, 2023
MEDICAL CARE TECHNOLOGIES INC |
dba Infinite Auctions, LLC |
Balance Sheet |
| |
March 31, | |
December 31, |
| |
2024 | |
2023 |
Assets | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash | |
$ | 27,120 | | |
| 35,388 | |
Prepaid expense | |
| 1,500 | | |
| 1,500 | |
Inventory | |
| 1,269,406 | | |
| 566,568 | |
Total Current Assets | |
| 1,298,026 | | |
| 603,456 | |
| |
| | | |
| | |
Total Assets | |
$ | 1,298,026 | | |
| 603,456 | |
| |
| | | |
| | |
Liabilities and Stockholder's Equity | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accrued expenses | |
$ | 10,622 | | |
| 8,043 | |
Credit Line | |
| 29,619 | | |
| 29,140 | |
Advances by Shareholder | |
| 58,357 | | |
| 22,293 | |
Note Payable | |
| | | |
| 10,000 | |
Total Current Liabilities | |
| 98,598 | | |
| 69,476 | |
| |
| | | |
| | |
Stockholder's Equity | |
| | | |
| | |
Preferred Stock; 0.00001 par value, 20,000,010 | |
| | | |
| | |
authorized, 128,901 shares issued and | |
| | | |
| | |
outstanding March 31,02024 and December | |
| | | |
| | |
31, 2023 | |
| 0 | | |
| 0 | |
Common Stock, 0.00001 par value, 7,979,999,990 | |
| | | |
| | |
shares authorized, 3,309,575,220 shares March | |
| | | |
| | |
31, 2024 and 3,209,575,220 December 31,2023 | |
| 33,096 | | |
| 32,096 | |
Additional Paid in Capital | |
| 12,010,995 | | |
| 11,311,995 | |
Accumulated Deficit | |
| (10,844,663 | ) | |
| (10,810,111 | ) |
Total Stockholder Equity | |
| 1,199,428 | | |
| 533,980 | |
| |
| | | |
| | |
Total Liabilities and Stockholder Equity | |
| 1,298,026 | | |
| 603,456 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL CARE TECHNOLOGIES INC |
dba Infinite Auctions, LLC |
Statement of Income |
| |
|
| |
For the Three Months Ended |
| |
March 31, |
| |
2024 | |
2023 |
| |
(Unaudited) | |
(Unaudited) |
| |
| |
|
Sales Revenue | |
| 7,114 | | |
| 122,706 | |
| |
| | | |
| | |
Cost of Sales | |
| 6,000 | | |
| 283,045 | |
| |
| | | |
| | |
Gross Profit | |
| 1,114 | | |
| (160,339 | ) |
| |
| | | |
| | |
General & Administrative | |
| 33,710 | | |
| 64,963 | |
| |
| | | |
| | |
NET OPERATING INCOME (LOSS) | |
| (32,596 | ) | |
| (225,302 | ) |
| |
| | | |
| | |
Other Income (Expense) | |
| | | |
| | |
Interest Expense | |
| (1,956 | ) | |
| (1,675 | ) |
| |
| | | |
| | |
NET INCOME | |
| (34,552 | ) | |
| (226,977 | ) |
The
accompanying notes are an integral part of these financial statements.
MEDICAL CARE TECHNOLOGIES INC |
dba Infinite Auctions, LLC |
Statement of Stockholders’ Equity |
| |
| |
| |
| |
| |
| |
| |
| |
|
| |
Common Stock | |
Special 2011 Series A
Preferred
Stock | |
Series A
Preferred Stock | |
Series B
Preferred
Stock | |
| |
| |
|
| |
Shares | |
Par value | |
Shares | |
Par value | |
Shares | |
Par value | |
Shares | |
Par value | |
Additional Paid In Capital | |
Accumulated Deficit | |
Total Stockholders’
Equity |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Balance - December 31, 2021 | |
| 2,959,575,220 | | |
$ | 29,596 | | |
| 1 | | |
$ | 0 | | |
| 1 | | |
$ | 0 | | |
| 129,800 | | |
$ | 1 | | |
$ | 11,492,473 | | |
$ | (11,522,070 | ) | |
$ | 0 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Cancellation of Common Stock | |
| (2,000,000,000 | ) | |
| (20,000 | ) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 20,000 | | |
| | | |
| 0 | |
Cancellation of Preferred Stock | |
| | | |
| | | |
| | | |
| | | |
| (1 | ) | |
| 0 | | |
| (129,800 | ) | |
| (1 | ) | |
| 1 | | |
| | | |
| 0 | |
Purchase of Infinite Auctions | |
| 2,250,000,000 | | |
| 22,500 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (200,479 | ) | |
| | | |
| (177,979 | ) |
Net Profit (Loss) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 1,099,465 | | |
| 1,099,465 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance December 31, 2022 | |
| 3,209,575,220 | | |
$ | 32,096 | | |
| 1 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
$ | 11,311,995 | | |
$ | (10,422,605 | ) | |
$ | 921,486 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Profit (Loss) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (387,506 | ) | |
| (387,506 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance - December 31, 2023 | |
| 3,209,575,220 | | |
$ | 32,096 | | |
| 1 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
| 0 | | |
$ | 11,311,995 | | |
$ | (10,810,111 | ) | |
$ | 533,980 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock issued for Inventory | |
| 100,000,000 | | |
| 1,000 | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 699,000 | | |
| | | |
| 700,000 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net Profit (Loss) | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| (34,552 | ) | |
| (34,552 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance - March 31, 2024 | |
| 3,309,575,220 | | |
$ | 33,096 | | |
| 1 | | |
$ | 0 | | |
| 0 | | |
$ | 0 | | |
| 0 | | |
$ | 0 | | |
$ | 12,010,995 | | |
$ | (10,844,663 | ) | |
$ | 1,199,428 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL CARE TECHNOLOGIES INC |
dba Infinite Auctions, LLC |
Statement of Cash Flows |
|
| |
For the Three Months Ended |
| |
March 31, |
| |
2024 | |
2023 |
| |
(Unaudited) | |
(Unaudited) |
| |
| |
|
Cash flows from Operations | |
| | | |
| | |
Net Loss | |
$ | (34,552 | ) | |
$ | (226,977 | ) |
Adjustments to reconcile net loss | |
| | | |
| | |
to net cash | |
| | | |
| | |
Prepaid expenses | |
| 0 | | |
| 0 | |
Inventory | |
| (706,288 | ) | |
| 287,300 | |
Accounts Payable | |
| 0 | | |
| (30,170 | ) |
Accrued expenses | |
| 2,579 | | |
| (11,261 | ) |
Credit line | |
| 479 | | |
| 1,039 | |
Advances by Shareholder | |
| 29,514 | | |
| 0 | |
Net Cash provided (used) by Operations | |
$ | (708,268 | ) | |
$ | 19,931 | |
| |
| | | |
| | |
| |
| | | |
| | |
Cash Flows from Investing activities | |
| 0 | | |
| 0 | |
| |
| | | |
| | |
Cash Flows from Financing activities | |
| | | |
| | |
Stock issued for Inventory | |
| 700,000 | | |
| 0 | |
Net Cash provided (used) by Financing | |
$ | 700,000 | | |
$ | 0 | |
| |
| | | |
| | |
| |
| | | |
| | |
Net increase (Decrease) in Cash | |
| (8,268 | ) | |
| 19,931 | |
| |
| | | |
| | |
Beginning Cash balance | |
| 35,388 | | |
| 11,797 | |
| |
| | | |
| | |
Ending Cash Balance | |
$ | 27,120 | | |
$ | 31,728 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL
CARE TECHNOLOGIES, INC.
NOTES
TO FINANCIAL STATEMENTS
MARCH
31, 2024
(Unaudited)
NOTE
1 – ORGANIZATION AND NATURE OF OPERATIONS
Medical
Technologies, Inc. (the “Company”, “we”, “us” or “our”), a Nevada corporation, has a
fiscal year end of December 31 and is listed on the OTC Pink Markets under the trading symbol MDCE. The Company had abandoned its business
and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements
with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2016 to 2021 which resulted
in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated
under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k)
of the Exchange Act. On May 13, 2021, a shareholder filed a petition for custodianship, with the District Court, Clark County, Nevada
and was appointed as the custodian of the Company on May 28, 2021. The Company’s Nevada charter was reinstated on June 4, 2021,
and all required reports were filed with the State of Nevada soon after. The Company remains inactive as of the date of this report and
is currently taking steps to provide adequate current public information to meet the requirements under the Securities Act of 1933. The
custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder
information hence the Company’s outstanding common shares were reflected in the equity section of the accompanying unaudited financial
statements for the periods ended March 31, 2024, and 2021.
The
issuer was incorporated in the State of Nevada in February 2007 as Aventerra Exploration, Inc. The issuer amended its Articles of Incorporation
to change its name to AM Oil Resources & Technology, Inc. in December 2008. The issuer merged with Medical Care Technologies, Inc.
and changed its name to Medical Care Technologies, Inc. in October 2009.
On
April 27, 2021, SSM Monopoly Corporation, a shareholder of the Company, served a demand to the Company, at the last address of record,
to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150.
On
May 13, 2021, a petition was filed against the Company in the District Court of Clark County, Nevada, entitled “In the Matter of
Medical Care Technologies, Inc., a Nevada corporation” under case number A-21-834558-C by SSM Monopoly Corporation, along with
an Application for Appointment of Custodian, after several attempts to locate prior management and reinstate the Company’s Nevada
charter, which had been revoked.
On
May 28, 2021, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of SSM Monopoly Corporation
LLC (the “Order”), as Custodian of the Company. Pursuant to the Order, the SSM Monopoly Corporation (the “Custodian”)
has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including,
but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering in contracts on behalf of the Company.
In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.
On
June 3, 2021, the Custodian appointed Kareem Mansour as the Company’s sole officer and director.
Also
on June 3, 2021, the Custodian designated one share of preferred stock as Special 2021 Series A Preferred Stock at par value of $0.00001.
The Special 2021 Series A Preferred has 60% voting rights over all classes of stock and is convertible into 3,000,000,000 shares of the
Company’s common stock.
Also
on June 3, 2021, the Custodian granted to itself, one share of preferred stock, Special 2021 Series A Preferred Stock at par value of
$0.00001.
On
June 4, 2021, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company’s
charter and appointed a new Resident Agent in Nevada.
On
June 14, 2021, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the “SPA”) with Krisa
Management LLC, a Texas limited liability company, to sell the Special 2021 Series A Preferred. Upon closing of the SPA on June 14, 2001,
Krisa Management LLC acquired 60% control of the Company. However, the court appointed control still remains with the Custodian until
the Custodian files a petition with the District Court of Clark County, Nevada to relinquish custodianship and control of the Company.
On
June 14, 2021, the Custodian appointed Carey W. Cooley as the Company’s sole officer and director. On June 14, 2021, Kareem Mansour
resigned as an officer and director.
On
August 19, 2021, in a private transaction, Krisa Management LLC entered into a tentative agreement with a private individual to sell
the Special 2021 Series A Preferred share. The sale is not yet closed and is awaiting a ruling on a pending motion in the State of Nevada.
On
November 12, 2021, the Custodian cancelled 2,000,000,000 shares of common stock that were improperly issued to the prior CEO, and all
shares of the Series A, B, and C Preferred Stock since they were improperly issued. The Custodian also revoked the Series A, B, and C
Preferred Stock designations as they were not properly established with the Secretary of State of the State of Nevada.
On
January 11, 2022, the District Court of Clark County, Nevada entered a Notice Of Entry Of Order Granting Custodian SSM Monopoly Corporation’s
Motion To Discharge Custodianship And Enter Final Order, which included the cancelation of 2,000,000,000 shares of common stock. However,
the wording of the order was insufficient to cancel the Series A, B, and C Preferred Stock.
On
May 6, 2022, the District Court of Clark County, Nevada entered an Amended Order, Nunc Pro Tunc, Granting Custodian SSM Monopoly Corporation’s
Motion To Discharge Custodianship And Enter Final Order, which included proper language to cancel the Series A, B, and C Preferred Stock
and revoke their designations.
As
of the date of this report, the company is a nonoperating holding company.
On
October 3, 2022, subsequent to the end of this reporting period, Krisa Management LLC completed its agreement from August 19, 2021, to
sell the Special 2021 Series A Preferred share to private individual, Marshall Perkins. The transaction is reflected on the Company’s
annual report for the period ending March 31, 2024.
On
October 3, 2022, subsequent to the end of this reporting period, the Company acquired Infinite Auctions LLC. Financials for the combined
companies are included in the Company’s annual report for the period ending March 31, 2024.
NOTE
2 – BASIS OF PRESENTATION AND GOING CONCERN
Basis
of Presentation
The
accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted
in the United States of America and the rules of the Security and Exchange Commission (“SEC”)
In
the opinion of the management all adjustments (which include normal recurring adjustments) necessary to present fairly the financial
position and the results of operations and cash flows presented have been reflected herein.
The
Company applies the provisions of FASB ASC Topic 740, Income Taxes. Topic 740 requires an asset and liability approach for financial
accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between
the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect
when such amounts are realized or settled. Due to a loss from inception, the Company has no tax liability. Deferred income tax assets
and liabilities are reflected at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities
are expected to be realized or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted
through the provision for income taxes
Basis
of Accounting
The
accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally
accepted in the United States.
Going
Concern
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which
contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently
has only incorporated a new operation though an accumulated deficit of $10,666,813 as of March 31, 2024. The Company intends to
commence operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be
certain that it will be successful in these strategies even with the required funding.
These
factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
NOTE
3 - SIGNIFICANT ACCOUNTING POLICIES
Use
of Estimates
The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
Cash
and Cash Equivalents
For
purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instructions
with original maturities of three months or less.
Financial
Instruments
The
FASB issued ASC 820-10, Fair Value Measurements and Disclosures, for financial assets and liabilities. ASC 820-10 provides a framework
for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price
that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous
market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy
which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs
required by the standard that the Company uses to measure fair value:
| - | Level
1: Quoted prices in active markets for identical assets or liabilities |
| - | Level
2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets
or liabilities; quoted prices in markets that are not
active, or other inputs that are observable or can be corroborated by observable market data
for substantially the full term of the related assets or liabilities. |
| - | Level
3: Unobservable inputs that are supported by little or no market activity and that are significant
to the fair value of the assets or liabilities. |
Concentrations and Credit Risks
The
Company’s financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales and accounts
receivable. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash
and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s
management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes
that any associated credit risk exposures are limited.
Foreign
Currency Translation
The
accounts of the Company are accounted for in accordance with the Statement of Financial Accounting Statements No. 52 (“SFAS
52”), “Foreign Currency Translation”. The financial statements of the Company are translated into US dollars as
follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and
shareholders’ equity at historical exchange rate. Monetary assets and liabilities, and the related revenue, expense, gain and
loss accounts, of the Company are re-measured at year-end exchange rates. Non-monetary assets and liabilities, and the related
revenue, expense, gain and loss accounts are re-measured at historical rates.
Adjustments
which result from the re-measurement of the assets and liabilities of the Company are included in net income.
Share-Based
Compensation
ASC
718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions
in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options,
and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees,
including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values.
That expense is recognized in the period of grant.
The
Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50,
Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair
value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value
of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
As
of March 31, 2024 and 2022, respectively, there was $Nil of unrecognized expense related to non-vested stock- based compensation arrangements
granted. There have been no options granted during the fiscal periods ended March 31, 2024 and 2022, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts
of existing assets and liabilities and their respective tax bases.
Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely
than not that the Company will not realize tax assets through future operations. Deferred tax assets or liabilities were offset by a
100% valuation allowance, therefore there has been no recognized benefit as of March 31, 2024 and 2022, respectively. Further it is unlikely
with the change of control that the Company will have the ability to realize any future tax benefits that may exist.
Commitments
and Contingencies
The
Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from
claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred
and the amount of the assessment can be reasonably estimated.
Earnings
Per Share
Net
income (loss) per share is calculated in accordance with ASC 260, Earnings Per Share. The weighted-average number of common shares outstanding
during each period is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted
average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares
assumed to be exercised.
Basic
net income (loss) per common share is based on the weighted average number of shares of common stock outstanding on March 31, 2024 and
2022. Due to prior net operating losses, there is no presentation of dilutive earnings per share, as it would be anti-dilutive.
Forgiveness
of Indebtedness
The
Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished
when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting
of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished
and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.
Recent
Accounting Pronouncements
We
have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements
will have a material impact on the Company.
In
August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815), which changes both the designation and measurement
guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity’s risk
management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial
and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item
in the financial statements.
FASB
ASU No. 2017-12 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual
reporting periods.
In
March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No.
2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance
changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies
will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital (“APIC”), but will instead
record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this
guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of
forfeitures on the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or
recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective
approach. All of the guidance will be effective for the Company in the fiscal year beginning January 1, 2018.
In
February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which establishes new accounting and disclosure requirements for
leases. FASB ASU No. 2016-02 requires lessees to classify most leases as either finance or operating leases and to initially recognize
a lease liability and right-of-use asset. Entities may elect to account for certain short-term leases (with a term of 12 months or less)
using a method similar to the current operating lease model. The statements of operations will include, for finance leases, separate
recognition of interest on the lease liability and amortization of the right-of-use asset and for operating leases, a single lease cost,
calculated so that the cost of the lease is allocated over the lease term on a straight-line basis.
In
July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory.
The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling
prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather
than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in,
first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15,
2016.
In
May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which requires an entity
to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU
2014-09 will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles when it becomes effective.
NOTE
4 - INCOME TAXES
Income
taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences
in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end.
A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the “more likely
than not” standard imposed by accounting standards to allow recognition of such an asset.
As
of March 31, 2024, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards.
Deferred tax assets were offset by a corresponding allowance of 100%.
The
Company experienced a change in control during the year, and therefore no more than an insignificant portion of this net operating allowance
will ever be used against future taxable income.
NOTE
5 – CONVERTIBLE NOTES PAYABLE
There
were no convertible notes payable during the period:
NOTE
6 - COMMITMENTS AND CONTINGENCIES
Risks
and Uncertainties
The
Company’s operations are subject to significant risks and uncertainties including financial, operational and regulatory risks,
including the potential risk of business failure. The Company has entered into no contracts during the year.
Legal
and other matters
In
the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's
management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the
Company’s financial position or results of operations.
NOTE
7 –- SUBSEQUENT EVENTS
Management
has evaluated subsequent events through the date of filing the consolidated financial statements with OTC Markets, the date the consolidated
financial statements were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance
sheet date that would have a material effect on the consolidated financial statements thereby requiring adjustment or disclosure.
MEDICAL
CARE TECHNOLOGIES INC.
FINANCIAL
STATEMENTS (Unaudited)
Year
Ended December 31, 2023
MEDICAL
CARE TECHNOLOGIES INC
dba
Infinite Auctions, LLC
Balance
Sheet
| |
December 31, 2023 (unaudited) | |
December 31, 2022 (unaudited) |
Assets | |
|
Current Assets | |
| | | |
| | |
Cash | |
$ | 35,388 | | |
$ | 11,797 | |
Prepaid expenses | |
| 1,500 | | |
| — | |
Inventories | |
| 566,568 | | |
| 1,033,700 | |
Total current assets | |
| 603,456 | | |
| 1,045,497 | |
| |
| | | |
| | |
Total assets | |
$ | 603,456 | | |
$ | 1,045,497 | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Accounts payable | |
$ | — | | |
$ | 54,000 | |
Accrued expenses | |
| 8,043 | | |
| 19,782 | |
Credit line | |
| 29,140 | | |
| 27,936 | |
Advances by Shareholder | |
| 22,293 | | |
| 22,293 | |
Notes Payable | |
| 10,000 | | |
| — | |
Total current liabilities | |
| 69,476 | | |
| 124,011 | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
Preferred Stock: 0.00001 par value, 20,000,010 shares authorized: | |
| | | |
| | |
Special 2021 Series A: 1 share outstanding as of December 31, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Series A Preferred Stock, 0 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Series B Preferred Stock, 0 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | |
| — | | |
| — | |
Common stock, $0.00001 par value; 7,979,999,990 shares authorized, 3,209,575,220 shares outstanding as of December 31, 2023 and December 31, 2022, respectively | |
| 32,096 | | |
| 32,096 | |
Additional paid-in capital | |
| 11,311,995 | | |
| 11,311,995 | |
Accumulated deficit | |
| (10,810,111 | ) | |
| (10,422,605 | ) |
Total stockholders’ equity | |
| 533,980 | | |
| 921,486 | |
Total liabilities and stockholders’ equity | |
$ | 603,456 | | |
$ | 1,045,497 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL
CARE TECHNOLOGIES INC
dba
Infinite Auctions, LLC
Income
Statement
| |
For the Year Ended December 31, |
| |
2023 | |
2022 |
Sales Revenues | |
$ | 731,971 | | |
$ | 3,469,685 | |
| |
| | | |
| | |
Cost of Goods Sold | |
| 789,208 | | |
| 2,139,685 | |
| |
| | | |
| | |
Gross Profit (Loss) | |
| (57,237 | ) | |
| 1,330,000 | |
| |
| | | |
| | |
Operating Expenses | |
| | | |
| | |
General and administrative expenses | |
| 323,784 | | |
| 230,895 | |
Total operating expenses | |
| 323,784 | | |
| 230,895 | |
Other Expense | |
| | | |
| | |
Interest Expense | |
| 6,485 | | |
| — | |
Total other expense | |
| 6,485 | | |
| — | |
Net Loss | |
$ | (387,506 | ) | |
$ | 1,099,105 | |
Earnings per Share | |
| | | |
| | |
Basic loss per share | |
$ | (0.00 | ) | |
$ | — | |
Weighted average shares outstanding | |
| 3,209,575,220 | | |
| 959,575,220 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL
CARE TECHNOLOGIES INC
dba
Infinite Auctions, LLC
Statements
of Changes in Stockholders’ Equity
| |
Special 2021 Series A Preferred Stock | |
Series A Preferred Stock | |
Series B Preferred Stock | |
Common Stock | |
| |
| |
|
| |
Shares | |
Amount | |
Shares | |
Amount | |
Shares | |
Amount | |
Shares | |
Amount | |
Additional Paid- in Capital | |
Accumulated
Deficit | |
Total Stockholders’
Equity |
Balance, January 1, 2022 | |
| 1 | | |
$ | — | | |
| 1 | | |
$ | — | | |
| 129,800 | | |
$ | 1 | | |
| 2,959,575,220 | | |
$ | 29,596 | | |
$ | 11,492,473 | | |
$ | (11,522,070 | ) | |
$ | (1 | ) |
Cancellation of common stock | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (2,000,000,000 | ) | |
| (20,000 | ) | |
| 20,000 | | |
| — | | |
| — | |
Cancellation of preferred stock | |
| — | | |
| — | | |
| (1 | ) | |
| — | | |
| (129,800 | ) | |
| (1 | ) | |
| — | | |
| — | | |
| 1 | | |
| — | | |
| — | |
Purchase of Infinite Auctions | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 2,250,000,000 | | |
| 22,500 | | |
| (200,479 | ) | |
| — | | |
| (177,979 | ) |
Net profit | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 1,099,465 | | |
| 1,099,465 | |
Balance, December 31, 2022 | |
| 1 | | |
$ | — | | |
| — | | |
$ | — | | |
| — | | |
$ | — | | |
| 3,209,575,220 | | |
$ | 32,096 | | |
$ | 11,311,995 | | |
$ | (10,422,605 | ) | |
$ | 921,486 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| (387,506 | ) | |
| (387,506 | ) |
Balance, December 31, 2023 | |
| 1 | | |
$ | — | | |
| — | | |
$ | — | | |
| — | | |
$ | — | | |
| 3,209,575,220 | | |
$ | 32,096 | | |
$ | 11,311,995 | | |
$ | (10,810,111 | ) | |
$ | 533,980 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
The
accompanying notes are an integral part of these financial statements
MEDICAL
CARE TECHNOLOGIES INC
dba
Infinite Auctions, LLC
Statement
of Cash Flows
| |
Year Ended December 31, |
| |
2023 | |
2022 |
Cash Flows from Operating Activities | |
| | | |
| | |
Net loss | |
$ | (387,506 | ) | |
$ | 1,099,465 | |
Adjustments to reconcile net loss to net cash and cash equivalents from operating activities: | |
| | | |
| | |
Interest expense on credit card and credit line | |
| 4,818 | | |
| — | |
Changes in operating assets and liabilities which provided cash: | |
| | | |
| | |
Prepaid expenses | |
| (1,500 | ) | |
| — | |
Inventories | |
| 467,332 | | |
| (1,033,700 | ) |
Accounts payable | |
| (54,000 | ) | |
| 54,000 | |
Accrued expenses | |
| (12,793 | ) | |
| 19,783 | |
Credit line | |
| 13,761 | | |
| — | |
Net cash provided by operating activities | |
| 29,912 | | |
| 139,548 | |
| |
| | | |
| | |
Cash Flows from Financing Activities | |
| | | |
| | |
Advances from credit line | |
| 1,000 | | |
| 27,936 | |
Payments to credit line | |
| (17,321 | ) | |
| — | |
Proceeds from Notes Payable | |
| 30,000 | | |
| — | |
Payments to Notes Payable | |
| (20,000 | ) | |
| — | |
Advances by Shareholders | |
| — | | |
| 22,293 | |
APIC Adjustment | |
| — | | |
| (177,979 | ) |
Net cash used in financing activities | |
| (6,321 | ) | |
| (127,750 | ) |
| |
| | | |
| | |
Net Increase in Cash | |
| 23,591 | | |
| 11,797 | |
Cash - Beginning of period | |
| 11,797 | | |
| — | |
Cash - End of period | |
$ | 35,388 | | |
$ | 11,797 | |
The
accompanying notes are an integral part of these financial statements.
MEDICAL
CARE TECHNOLOGIES, INC.
NOTES
TO FINANCIAL STATEMENTS
December
31, 2023
(Unaudited)
NOTE
1 – ORGANIZATION AND NATURE OF OPERATIONS
Medical
Technologies, Inc. (the “Company”, “we”, “us” or “our”), a Nevada corporation, has a
fiscal year end of December 31 and is listed on the OTC Pink Markets under the trading symbol MDCE. The Company had abandoned its business
and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements
with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2016 to 2021 which resulted
in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated
under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k)
of the Exchange Act. On May 13, 2021, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada
and was appointed as the custodian of the Company on May 28, 2021. The Company’s Nevada charter was reinstated on June 4, 2021,
and all required reports were filed with the State of Nevada soon after. The Company remains inactive as of the date of this report and
is currently taking steps to provide adequate current public information to meet the requirements under the Securities Act of 1933. The
custodian was not able to recover any of the Company’s accounting records from previous management but was able to get the shareholder
information hence the Company’s outstanding common shares were reflected in the equity section of the accompanying unaudited financial
statements for the year ended December 31, 2023, and December 31, 2022.
The
issuer was incorporated in the State of Nevada in February 2007 as Aventerra Exploration, Inc. The issuer amended its Articles of Incorporation
to change its name to AM Oil Resources & Technology, Inc. in December 2008. The issuer merged with Medical Care Technologies, Inc.
and changed its name to Medical Care Technologies, Inc. in October 2009.
On
October 3, 2022, Krisa Management LLC completed its agreement from August 19, 2021, to sell the Special 2021 Series A Preferred share
to private individual, Marshall Perkins. The Company acquired Infinite Auctions LLC. The transaction is reflected on the Company’s
annual report for the period ending December 31, 2022. Financials for the combined companies are included in the Company’s annual
report for the period ending December 31, 2022.
NOTE
2 – BASIS OF PRESENTATION AND GOING CONCERN
Basis
of Presentation
The
accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted
in the United States of America and the rules of the Security and Exchange Commission (“SEC”)
In
the opinion of management all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position
and the results of operations and cash flows presented have been reflected herein.
The
Company applies the provisions of FASB ASC Topic 740, Income Taxes. Topic 740 requires an asset and liability approach for financial
accounting and reporting for income taxes, and the recognition of deferred tax assets and liabilities for the temporary differences between
the financial reporting basis and tax basis of the Company’s assets and liabilities at enacted tax rates expected to be in effect
when such amounts are realized or settled. Due to a loss from inception, the Company has no tax liability. Deferred income tax assets
and liabilities are reflected at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities
are expected to be realized or settled. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted
through the provision for income taxes.
Basis
of Accounting
The
accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally
accepted in the United States.
Going
Concern
The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates
the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has only incorporated
a new operation though an accumulated deficit of $11,039,080 as of December 31, 2023. The Company intends to commence operations as set
out below and raise the necessary funds to carry out the strategies. The Company cannot be certain that it will be successful in these
strategies even with the required funding.
These
factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial
statements do not include any adjustments that might result from the outcome of this uncertainty.
NOTE
3 - SIGNIFICANT ACCOUNTING POLICIES
Use
of Estimates
The
preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual
results could differ from those estimates.
Cash
and Cash Equivalents
For
purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instructions
with original maturities of three months or less.
Financial
Instruments
The
FASB issued ASC 820-10, Fair Value Measurements and Disclosures, for financial assets and liabilities. ASC 820-10 provides a framework
for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price
that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous
market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy
which requires an entity to maximize the use of observable inputs, where available.
The
following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:
| - | Level
1: Quoted prices in active markets for identical assets or liabilities |
| - | Level
2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets
or liabilities; quoted
prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially
the full term of the related assets or liabilities. |
| - | Level
3: Unobservable inputs that are supported by little or no market activity and that are significant
to the fair value of the assets or liabilities. |
The
Company’s financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales and accounts
receivable. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash
and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company’s
management plans to assess the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes
that any associated credit risk exposures are limited.
Share-Based
Compensation
ASC
718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions
in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options,
and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees,
including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values.
That expense is recognized in the period of grant.
The
Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50,
Equity – Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair
value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value
of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
For
the year ended December 31, 2023 and 2022, respectively, there were no unrecognized expenses related to non-vested stock- based compensation
arrangements granted. There have been no options granted during the year ended December 31, 2023 and December 31, 2022, respectively.
Income
Taxes
The
Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and
liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts
of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax
rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs.
A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax
assets through future operations. Deferred tax assets or liabilities were offset by a 100% valuation allowance, therefore there has been
no recognized benefit as of December 31, 2023 and December 31, 2022, respectively. Further it is unlikely with the change of control
that the Company will have the ability to realize any future tax benefits that may exist.
Commitments
and Contingencies
The
Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from
claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred
and the amount of the assessment can be reasonably estimated.
Earnings
Per Share
Net
income (loss) per share is calculated in accordance with ASC 260, Earnings Per Share. The weighted-average number of common shares outstanding
during each period is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted
average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares
assumed to be exercised.
Basic
net income (loss) per common share is based on the weighted average number of shares of common stock outstanding for
the year ended December 31, 2023 and 2022. Due to prior net operating losses, there is no presentation of dilutive earnings per
share, as it would be anti-dilutive.
Forgiveness
of Indebtedness
The
Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished
when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting
of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished
and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.
NOTE
4 - INCOME TAXES
Income
taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences
in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end.
A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the “more likely
than not” standard imposed by accounting standards to allow recognition of such an asset.
As
of December 31, 2023, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards.
Deferred tax assets were offset by a corresponding allowance of 100%.
NOTE
5 - COMMITMENTS AND CONTINGENCIES
Risks
and Uncertainties
The
Company’s operations are subject to significant risks and uncertainties including financial, operational and regulatory risks,
including the potential risk of business failure. The Company has entered into no material contracts during the year.
Legal
and other matters
In
the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's
management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the
Company’s financial position or results of operations.
NOTE
6 – EFFECT OF MERGER IN PRESENTATION
As
of October 3, 2022, Infinite Auctions, LLC was merged into Medical Care Technologies Inc. For the purposes of the presentation of these
financial statements, the financial operation of Infinite Auctions Inc. for the year ended December 31, 2022 is not presented. Had they
been combined as of December 31, 2022, the statements would have looked as follows:
Combined
Balance Sheets
ASSETS | |
|
Current Assets | |
$ | 1,045,960 | |
LIABILITIES | |
| | |
Current Liabilities | |
| 125,151 | |
STOCKHOLDERS’ EQUITY | |
$ | 920,809 | |
Combined Income Statements
Revenue | |
$ | 3,469,685 | |
Cost of Goods Sold | |
| 2,139,325 | |
Administrative Expenses | |
| 231,490 | |
Net Income | |
$ | 1,098,870 | |
NOTE
7 - SUBSEQUENT EVENTS
Management
has evaluated subsequent events through the date of filing the consolidated financial statements with OTC Markets, the date the consolidated
financial statements were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance
sheet date that would have a material effect on the consolidated financial statements thereby requiring adjustment or disclosure.
PART
III - INFORMATION NOT REQUIRED IN THE OFFERING CIRCULAR
SIGNATURES
Pursuant
to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all the requirements
for filing on Form 1-A and has duly caused this Offering Circular to be signed on its behalf by the undersigned on the August 9, 2024.
Medical Care Technologies Corp. |
|
|
|
|
By: |
/s/ Marshall
Perkins III |
|
Name: |
Marshall Perkins III |
|
Title: |
Chief Executive Officer, President, Secretary, Treasurer,
and Director |
|
Date:
August 9, 2024
This
offering circular has been signed by the following person in the capacities indicated on the 9th day of August 2024.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/
Marshall Perkins III |
|
Chief
Executive Officer, President, Secretary, Treasurer and Director |
|
August
9, 2024 |
Marshall Perkins III |
|
|
|
Exhibit 2.1
Exhibit 2.2
AMENDED
AND RESTATED BYLAWS
OF
Medical
Care Technologies Inc.
The
annual meeting of the shareholders of this Corporation,
for the purpose of election of Directors
and for such other business as may come before it,
shall be held at the registered office
of the Corporation, or such other places,
either within or without the State of
Nevada, as
may be designated by the notice of the meeting,
on the first week in February of each
and every year, at 1:00 p.m.,
commencing in 2021 but in case such day shall
be a legal holiday, the
meeting shall be held at the same hour and place on the next succeeding day not a holiday.
Special
meetings of the shareholders of this Corporation may be called at any time by the holders often percent (10%) of the voting shares of
the Corporation, or
by the President, or by the Board of Directors or a majority thereof. No business shall be transacted at any special meeting of shareholders
except as is specified in the notice calling for said meeting. The Board of Directors may designate any place,
either within or without the State of
Nevada, as
the place of any special meeting called by the president or the Board of Directors,
and special meetings called at the request
of shareholders shall be held at such place in the State of Nevada,
as may be determined by the Board of
Directors and placed in the notice of such meeting.
Written
notice of annual or special meetings of shareholders stating the place,
day,
and hour of the meeting and,
in the case of a special meeting,
the purpose or purposes for which the
meeting is called shall be given by the secretary or persons authorized to call the meeting to each shareholder of record entitled to
vote at the meeting. Such
notice shall be given not less than ten (10) nor more than fifty (50) days prior to the date of the meeting,
and such notice shall be deemed to be
delivered when deposited in the United States mail addressed to the shareholder at his/her address as it appears on the stock transfer
books of the Corporation.
Notice
of the time, place, and purpose of any meeting may be waived in writing and will be waived by any shareholder by his/her attendance thereat
in person or by proxy. Any shareholder so waiving shall be bound by the proceedings of any such meeting in all respects as if due notice
thereof had been given.
| .05 | Quorum
and Adjourned Meetings. |
A
majority of the outstanding shares of the Corporation entitled to vote, represented in person or by proxy, shall constitute a quorum
at a meeting of shareholders. A majority of the shares represented at a meeting, even if less than a quorum, may adjourn the meeting
from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented,
any business may be transacted which
might have been transacted at the meeting as originally notified. The shareholders present at a duly organized meeting may continue to
transact business until adjournment, notwithstanding the withdrawal of enough shareholders to leave less than a quorum.
At
all meetings of shareholders, a shareholder may vote
by proxy executed in writing by the
shareholder or by his/her duly authorized attorney in fact. Such proxy shall be filed with the secretary of the Corporation before or
at the time of the meeting. No proxy shall be valid after eleven (11) months from the date of its execution, unless otherwise provided
in the proxy.
Except
as otherwise provided in the Articles
of Incorporation or in these Bylaws, every shareholder of record shall have the right at every shareholder's meeting to one (1) vote
for every share standing in his/her name on the books of the Corporation, and the affirmative vote of a majority of the shares represented
at a meeting and entitled to vote thereat shall be necessary for the adoption of a motion or for the determination of all questions and
business which shall come before the meeting.
The
business and affairs of the Corporation shall be managed by its Board of Directors.
| .02 | Number,
Tenure and Qualifications. |
The
number of Directors of the Corporation shall be not less than one nor more than thirteen. Each Director shall hold office until the next
annual meeting of shareholders and until his/her successor shall have been elected and qualified. Directors need not be residents of
the State of Nevada or shareholders of the Corporation.
The
Directors shall be elected by the shareholders at their annual meeting each year; and if,
for any cause the Directors shall not
have been elected at an annual meeting, they may be elected at a special meeting of shareholders called for that purpose in the manner
provided by these Bylaws.
In
case of any vacancy in the Board of Directors,
the remaining Directors,
whether constituting a quorum or not,
may elect a successor to hold office
for the unexpired portion of the terms of the Directors whose place shall be vacant, and until his/her successor shall have been duly
elected and qualified. Further,
the remaining Directors may fill any empty
seats on the Board of Directors even if the empty seats have never been occupied.
Any
Director may resign at any time by delivering written notice to the secretary of the Corporation.
At
any annual, special,
or regular meeting of the Board of Directors,
any business may be transacted,
and the Board may exercise all of its
powers. Any such annual, special
or regular meeting of the Board of Directors of the Corporation may be held outside of the State of Nevada, and any member or members
of the Board of Directors of the Corporation may participate in any such meeting by means of a conference telephone or similar communications
equipment by means of which all persons participating in the meeting can hear each other at the same time;
the participation by such means shall
constitute presence in person at such meeting.
| A. | Annual
Meeting of Directors. |
Annual
meetings of the Board of Directors shall be held immediately after the annual shareholders' meeting or at such time and place as may
be determined by the Directors. No notice of the annual meeting of the Board of Directors shall be necessary.
Special
meetings of the Directors shall be called at any time and place upon the call of the president or any Director. Notice of the time and
place of each special meeting shall be given by the secretary, or the persons calling the meeting, by mail, radio, telegram, or by personal
communication by telephone or otherwise at least one (1) day in advance of the time of the meeting. The purpose of the meeting need not
be given in the notice. Notice of any special meeting may be waived in writing or by telegram (either before or after such meeting) and
will be waived by any Director in attendance at such meeting.
| C. | Regular
Meetings of Directors. |
Regular
meetings of the Board of Directors shall be held at such place and on such day and hour as shall from time to time be fixed by resolution
of the Board of Directors. No notice of regular meetings of the Board of Directors shall be necessary.
A
majority of the Directors presently in office shall constitute a quorum for all purposes, but a lesser number may adjourn any meeting,
and the meeting may be held as adjourned without further notice. At each meeting of the Board at which a quorum is present, the act of
a majority of the Directors present at the meeting shall be the act of the Board of Directors. The Directors present at a duly organized
meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough Directors to leave less than a
quorum.
By
resolution of the Board of Directors, the Directors may be paid their expenses, if any, of attendance at each meeting of the Board of
Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as Director. No such
payment shall preclude any Director from serving the Corporation in any other capacity and receiving compensation therefore.
| .09 | Presumption
of Assent. |
A
Director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall
be presumed to have assented to the action taken unless his/her dissent shall be entered in the minutes of the meeting or unless he/she
shall file his/her written dissent to such action with the person acting as the secretary of the meeting before the adjournment thereof
or shall forward such dissent by registered mail to the secretary of the Corporation immediately after the adjournment of the meeting.
Such right to dissent shall not apply to a Director who voted in favor of such action.
| .10 | Executive
and Other Committees. |
The
Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members an executive
committee and one of more other committees, each of which, to the extent provided in such resolution, shall have and may exercise all
the authority of the Board of Directors, but no such committee shall have the authority of the Board of Directors, in reference to amending
the Articles of Incorporation, adoption of a plan of merger or consolidation, recommending to the shareholders the sale, lease, exchange,
or other disposition of all or substantially all the property and assets of the dissolution of the Corporation or a revocation thereof,
designation of any such committee and the delegation thereto of authority shall not operate to relieve any member of the Board of Directors
of any responsibility imposed by law.
| .11 | Chairman
of Board of Directors. |
The
Board of Directors may, in its discretion, elect a chairman of the Board of Directors from its members; and, if a chairman has been elected,
he/she shall, when present, preside at all meetings of the Board of Directors and the shareholders and shall have such other powers as
the Board may prescribe.
Directors
may be removed from office with or without cause by a vote of shareholders holding a majority of the shares entitled to vote at an election
of Directors.
| III. | ACTIONS
BY WRITTEN CONSENT. |
Any
corporate action required by the Articles of Incorporation, Bylaws, or the laws under which this
Corporation is formed, to be voted upon or approved at a duly called meeting of the Directors may be accomplished without a meeting
if a written memorandum setting forth the action so taken, shall be signed by all the Directors. Any corporate action required by the
Articles of Incorporation, Bylaws, or the laws under which this Corporation is formed, to be voted upon or approved at a duly called
meeting of the Shareholders, may be accomplished without a meeting if a written memorandum setting forth the action so taken, shall be
signed by holders of a majority of the total outstanding shares of common stock.
The
Officers of the Corporation shall be a president, one or more vice presidents (the number thereof to be determined by the Board of Directors),
a secretary and a treasurer, each of whom shall be elected by the Board of Directors. Such other Officers and assistant officers as may
be deemed necessary may be elected or appointed by the Board of Directors. Any Officer may be held by the same person, except that in
the event that the Corporation shall have more than one director, the offices of president and secretary shall be held by different persons.
| .02 | Election,
Qualification and Term of Office. |
Each
of the Officers shall be elected by the Board of Directors. None of said Officers except the president need be a Director, but a vice
president who is not a Director cannot succeed to or fill the office of president. The Officers shall be elected by the Board of Directors.
Except as
hereinafter provide, each of said Officers shall hold office from the date of his/her election until the
next annual meeting of the
Board of Directors
and until his/her successor shall have been duly elected
and qualified.
The
powers and duties of the respective corporate Officers shall be as follows:
The
president shall be the chief executive Officer of the Corporation and, subject to the direction and control of the Board of Directors,
shall have general charge and supervision over its property, business, and affairs, including but not limited to functioning as the secretary
and treasurer of the Corporation if the secretary or treasurer is unable to perform his/her duties. He/she shall, unless a Chairman of
the Board of Directors has been elected and is present, preside at meetings of the shareholders and the Board of Directors.
In
the absence of the president or his/her inability to act, the senior vice president shall act in his place and stead and shall have all
the powers and authority of the president,
except as limited by resolution of the
Board of Directors.
The
secretary shall be responsible for:
| 1. | Keeping
the minutes of the shareholder's and of the Board of Directors meetings in one or more books
provided for that purpose; |
| 2. | Seeing
that all notices are duly given in accordance with the provisions of these Bylaws or as required
by law; |
| 3. | Be
custodian of the corporate records and of the seal of the Corporation and affix the seal
of the Corporation to all documents as may be required; |
| 4. | Keeping
a register of the post office address of each shareholder which shall be furnished to the
secretary by such shareholder; |
| 5. | Signing
with the president, or a vice president, certificates for shares of the Corporation, the
issuance of which shall have been authorized by resolution of the Board of Directors; |
| 6. | Having
general charge of the stock transfer books of the corporation; and, |
| 7. | In
general, perform all duties incident to the office of secretary and such other duties as
from time to time may be assigned to him/her by the president or by the Board of Directors. |
Subject
to the direction and control of the Board of Directors, the treasurer shall have the custody, control and disposition of the funds and
securities of the Corporation and shall account for the same; and, at the expiration of his/her term of office, he/she shall turn over
to his/her successor all property of the Corporation in his/her possession.
| E. | Assistant
Secretaries and Assistant
Treasurers. |
The
assistant secretaries, when authorized by the Board of Directors, may sign with the president, or a vice president, certificates for
shares of the Corporation the issuance of which shall have been authorized by a resolution of the Board of Directors. The assistant treasurers
shall, respectively, if required by the Board of Directors, give bonds for the faithful discharge of their duties in such sums and with
such sureties as the Board of Directors shall determine. The assistant secretaries and assistant treasurers, in general, shall perform
such duties as shall be assigned to them by the secretary or the treasurer, respectively, or by the president or the Board of Directors.
The
Board of Directors shall have the right to remove any Officer whenever in its judgment the best interest of the Corporation will be served
thereby.
The
Board of Directors shall fill any office which becomes vacant with a successor who shall hold office for the unexpired term and until
his/her successor shall have been duly elected and qualified.
The
salaries of all Officers of the Corporation shall be fixed by the Board of Directors.
| .01 | Form
and Execution of Certificates. |
Certificates
for shares of the Corporation shall be in such form as is consistent with the provisions of
the Corporation laws of the State of Nevada. They shall be signed by the president and by the secretary,
and the seal of the Corporation shall
be affixed thereto. Certificates
may be issued for fractional shares.
Shares
may be transferred by delivery of the certificates therefore,
accompanied either by an assignment
in writing on the back of the certificates or by a written power of attorney to assign and transfer the same signed by the record holder
of the certificate. Except as otherwise specifically provided in these Bylaws,
no shares shall be transferred on the
books of the Corporation until the outstanding certificate therefore has been surrendered to the Corporation.
| .03 | Loss
or Destruction of Certificates. |
In
case of loss or destruction of any certificate of shares,
another may be issued in its place upon
proof of such loss or destruction and upon the giving of a satisfactory bond of indemnity to the Corporation. A new certificate may be
issued without requiring any bond,
when in the judgment of the Board of Directors
it is proper to do so.
| .01 | Books
of Accounts, Minutes and Share Register. |
The
Corporation shall keep complete books and records of accounts and minutes of the proceedings of
the Board of Directors and shareholders
and shall keep at its registered office,
principal place of business,
or at the office of its transfer agent
or registrar a share register giving the names of the shareholders in alphabetical order and showing their respective addresses and the
number of shares held by each.
| .02 | Copies
of Resolutions. |
Any
person dealing with the Corporation may rely upon a copy
of any of the records of
the proceedings,
resolutions, or votes of the Board of
Directors or shareholders, when
certified by the president or secretary.
The
Corporation is not required to have a corporate seal.
No
loans shall be made by the Corporation to its Officers or Directors
| IX. | INDEMNIFICATION
OF DIRECTORS AND OFFICERS. |
The
Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any proceeding,
whether civil,
criminal,
administrative or investigative (other
than an action by or in the right of the Corporation) by reason of the fact that such person is or was a Director,
Trustee, Officer,
employee or agent of the Corporation,
or is or was serving at the request
of the Corporation as a Director, Trustee,
Officer,
employee or agent of another corporation,
partnership,
joint venture,
trust or other enterprise,
against expenses (including attorneys'
fees),judgment,
fines and amounts paid in settlement
actually and reasonably incurred by such person in connection with such action,
suit or proceeding if such person acted
in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of
the Corporation,
and with respect
to any criminal action or proceeding,
had no reasonable
cause to believe such person's
conduct was unlawful. The termination of any action,
suit or proceeding by judgment,
order, settlement,
conviction,
or upon a plea of nolo contendere or
its equivalent, shall
not, of
itself, create
a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed
to the best interests of the Corporation, and with respect to any criminal action proceeding,
had reasonable
cause to believe
that such person's
conduct was unlawful.
The
Corporation shall indemnify
any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or
in the
right of the Corporation to procure a judgment in the Corporation's favor by reason of the fact that such person is or was a Director,
Trustee, Officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a Director, Trustee,
Officer, employee or agent of another corporation, partnership, joint venture,
trust or other enterprise, against expenses
(including attorney's
fees) and amount paid in settlement actually and reasonably incurred by such person in connection with the defense or settlement of such
action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best
interests of the Corporation, and, with respect to amounts paid in settlement, the settlement of the suit or action was in the best interests
of the Corporation; provided, however, that no indemnification shall be made in respect of any claim, issue or matter as to which such
person shall have been adjudged to be liable for gross negligence or willful misconduct in the performance of such person's duty to the
Corporation unless and only to the extent that, the court in which such action or suit was brought shall determine upon application that,
despite circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as such court shall deem
proper. The termination of any action or suit by judgment or settlement shall not, of itself, create a presumption that the person did
not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation.
To
the extent that a Director, Trustee,
Officer, employee or Agent of the Corporation has been successful on the merits or otherwise, in whole or in part in defense of any action,
suit or proceeding referred to in Paragraphs .01
and .02
above, or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by
such person in connection therewith.
Any
indemnification under Paragraphs .01 and .02 above (unless ordered by a court) shall be made by the Corporation only as authorized in
the specific case upon a determination that indemnification of the Director, Trustee, Officer, employee, or agent is proper in the circumstances
because such person has met the applicable standard of conduct set forth in Paragraphs .01 and .02 above. Such determination shall be
made (a) by the Board of Directors of the Corporation by a majority vote of a quorum consisting of Directors who were not parties to
such action, suit or proceeding, or (b) is such a quorum is not obtainable, by a majority vote of the Directors who were not parties
to such action, suit or proceeding, or (c) by independent legal counsel (selected by one or more of the Directors, whether or not a quorum
and whether or not disinterested) in a written opinion, or (d) by the Shareholders. Anyone making such a determination under this Paragraph
..04 may determine that a person has met the standards therein set forth as to some claims, issues or matters but not as to others, and
may reasonably prorate amounts to be paid as indemnification.
Expenses
incurred in defending civil or criminal action,
suit or proceeding shall be paid by
the Corporation, at
any time or from time to time in advance of the final disposition of such action,
suit or proceeding as authorized in
the manner provided in Paragraph .04 above upon receipt of an undertaking by or on behalf of the Director,
Trustee,
Officer,
employee,
or agent to repay such amount unless
it shall ultimately be by the Corporation is authorized in this Section.
The
indemnification provided in this Section shall not be deemed exclusive of any other rights to which those indemnified may be entitled
under any law, bylaw,
agreement,
vote of shareholders or disinterested
Directors or otherwise, both
as to action in such person's
official capacity and as to action in another capacity while holding such office,
and shall continue as to a person who
has ceased to be a Director,
Trustee,
Officer,
employee or agent and shall inure to
the benefit of the heirs, executors,
and administrators of such a person.
The
Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a Director,
Trustee,
Officer,
employee or agent of the Corporation,
or is or was serving at the request of the Corporation as a Director,
Trustee,
Officer,
employee,
or agent of another corporation,
partnership,
joint venture, trust or other enterprise,
against any liability assessed against
such person in any such capacity or arising out of such person's status as such,
whether or not the corporation would
have the power to indemnify such person against such liability.
| .08 | "Corporation"
Defined. |
For
purposes of this Section, references
to the "Corporation"
shall include,
in addition to the Corporation,
an constituent corporation (including
any constituent of a constituent) absorbed in a consolidation or merger which,
if its separate
existence had continued, would have had the power and
authority to indemnify its Directors,
Trustees,
Officers,
employees,
or agents,
so that any person who is or was a Director,
Trustee,
Officer,
employee or agent of such constituent
corporation or of any entity a majority of the voting stock of which is owned by such constituent corporation or is or was serving at
the request of such constituent corporation as a Director,
Trustee,
Officer,
employee,
or agent of the corporation,
partnership,
joint venture,
trust or other enterprise,
shall stand in the same position under
the provisions of this Section with respect to the resulting or surviving Corporation as such person would have with respect to such
constituent corporation if its separate existence had continued.
These
Bylaws may be amended, altered, or repealed at any regular or special meeting of the shareholders if notice of the proposed alteration
or amendment is contained in the notice of the meeting.
|
.02 |
By the Board of Directors. |
These
Bylaws may be amended, altered, or repealed by the affirmative vote of a majority of the entire Board of Directors at any regular or
special meeting of the Board.
The
fiscal year
of the Corporation
shall be set by resolution of the Board of
Directors.
The
rules contained in the most recent edition of Robert's Rules or Order, Newly Revised, shall govern all meetings of shareholders and Directors
where those rules are not inconsistent with the Articles of Incorporation, Bylaws, or special rules or order of the Corporation.
| XIII. | REIMBURSEMENT
OF DISALLOWED EXPENSES. |
If
any salary, payment, reimbursement, employee fringe benefit, expense allowance payment, or other expense incurred by the Corporation
for the benefit of an employee is disallowed in whole or in part as·a
deductible expense of the Corporation for Federal Income Tax purposes, the employee shall reimburse the Corporation, upon notice and
demand, to the full extent of the disallowance. This legally enforceable obligation is in accordance with the provisions of Revenue Ruling
69115, 19691 C.B. 50, and is for the purpose of entitling such employee to a business expense deduction for the taxable year in which
the repayment is made to the Corporation. In this manner, the Corporation shall be protected from having to bear the entire burden of
disallowed expense items.
Executed
this 30th day of June 2023
Corporate
Secretary
Exhibit 4.1
MEDICAL
CARE TECHNOLOGIES INC.
SUBSCRIPTION
AGREEMENT
NOTICE
TO INVESTORS
THIS
INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE
PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID
AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES.
THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A
REGISTRATION STATEMENT UNDER THE ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION
OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY
OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO PROSPECTIVE INVESTOR IN CONNECTION WITH THIS OFFERING.
ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.
THE
SECURITIES CANNOT BE SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE SECURITIES ACT. IN ADDITION, THE SECURITIES CANNOT BE
SOLD OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. INVESTORS
WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE SECURITIES
ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4(g). THE COMPANY IS RELYING ON THE REPRESENTATIONS
AND WARRANTIES SET FORTH BY EACH INVESTOR IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY INVESTOR IN CONNECTION
WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT.
PROSPECTIVE
INVESTORS MAY NOT TREAT THE CONTENTS OF THE SUBSCRIPTION AGREEMENT, THE OFFERING CIRCULAR OR ANY OF THE OTHER MATERIALS PROVIDED BY THE
COMPANY (COLLECTIVELY, THE “OFFERING MATERIALS”), OR ANY PRIOR OR SUBSEQUENT COMMUNICATIONS FROM THE COMPANY OR ANY
OF ITS OFFICERS, EMPLOYEES OR AGENTS (INCLUDING “TESTING THE WATERS” MATERIALS) AS INVESTMENT, LEGAL OR TAX ADVICE.
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THIS OFFERING, INCLUDING
THE MERITS AND THE RISKS INVOLVED. EACH PROSPECTIVE INVESTOR SHOULD CONSULT THE INVESTOR’S OWN COUNSEL, ACCOUNTANTS AND OTHER PROFESSIONAL
ADVISORS AS TO INVESTMENT, LEGAL, TAX AND OTHER RELATED MATTERS CONCERNING THE INVESTOR’S PROPOSED INVESTMENT.
THE
OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS
PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION
CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,”
“PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT”
AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE
FORWARD LOOKING STATEMENTS. THESE STATEMENTS
REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE
COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT
TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES
NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE
OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
SUBSCRIPTION
AGREEMENT
This
subscription agreement (this “Subscription Agreement” or the “Agreement”) is entered into by and
between MEDICAL CARE TECHNOLOGIES INC., a Nevada corporation (hereinafter the “Company”) and the undersigned
(hereinafter the “Investor”) as of the date set forth on the signature page hereto. Any term used but not defined
herein shall have the meaning set forth in the Offering Circular (as defined below).
RECITALS
WHEREAS,
the Company desires to offer shares of its common stock, par value $0.001 per share (the “Common Stock”) on a “best
efforts” basis pursuant to Regulation A of Section 3(6) of the Securities Act of 1933, as amended (the “Securities
Act”), pursuant to a Tier 1 offering (the “Offering”), at a purchase price of $.__ per share (the “Per
Share Purchase Price”), for total gross proceeds of up to $1,000,000 (the “Maximum Offering”); and
WHEREAS,
the Investor desires to acquire that number of shares of Common Stock (the “Shares”) as set forth on the signature
page hereto at the purchase price set forth herein; and
WHEREAS,
the Offering will terminate on the first to occur of: (i) one year from the date of the Offering Circular as filed with the US Securities
and Exchange Commission; or (ii) the date on which the Maximum Offering is sold (in either case, the “Termination Date”).
NOW,
THEREFORE, for and in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby
agree as follows:
1. Subscription.
(a)
The Investor hereby irrevocably subscribes for and agrees to purchase the number of Shares set forth on the signature page hereto at
the Per Share Purchase Price, upon the terms and conditions set forth herein. The aggregate purchase price for the Shares with respect
to each Investor (the “Purchase Price”) is payable in the manner provided in Section 2(a) below.
(b)
Investor understands that the Shares are being offered pursuant to the Form 1-A Regulation A Offering Circular dated _____________, 2024
and its exhibits as filed with and qualified by the Securities and Exchange Commission (the “SEC”) on______________,
2024 (collectively, the “Offering Circular”). The Company will accept tenders of funds to purchase the Shares. The
Company will close on investments on a “rolling basis,” pursuant to the terms of the Offering Circular. As a result,
not all investors will receive their Shares on the same date.
(c)
This subscription may be accepted or rejected in whole or in part, for any reason or for no reason, at any time prior to the Termination
Date, by the Company at its sole and absolute discretion. In addition, the Company, at its sole and absolute discretion, may allocate
to Investor only a portion of the number of the Shares that Investor has subscribed for hereunder. The Company will notify Investor whether
this subscription is accepted (whether in whole or in part) or rejected. If Investor’s subscription is rejected, Investor’s
payment (or portion thereof if partially rejected) will be returned to Investor without interest and all of Investor’s obligations
hereunder shall terminate. In the event of rejection of this subscription in its
entirety, or in the event the sale of the Shares (or
any portion thereof) to an Investor is not consummated for any reason, this Subscription Agreement shall have no force or effect, except
for Section 5 hereof, which shall remain in full force and effect.
(d)
The terms of this Subscription Agreement shall be binding upon Investor and its permitted transferees, heirs, successors and assigns
(collectively, the “Transferees”); provided, however, that for any such transfer to be deemed effective, the Transferee
shall have executed and delivered to the Company in advance an instrument in form acceptable to the Company in its sole discretion, pursuant
to which the proposed Transferee shall acknowledge and agree to be bound by the representations and warranties of Investor and the terms
of this Subscription Agreement. No transfer of this Agreement may be made without the consent of the Company, which may be withheld in
its sole and absolute discretion.
2. Payment
and Purchase Procedure. The Purchase Price shall be paid simultaneously with Investor’s subscription. Investor shall deliver
payment for the aggregate purchase price of the Shares by check, credit card, ACH deposit or by wire transfer to an account designated
by the Company in Section 8 below. The Investor acknowledges that, in order to subscribe for Shares, he must fully comply
with the purchase procedure requirements set forth in Section 8 below.
3. Representations
and Warranties of the Company. The Company represents and warrants to Investor that the following representations and warranties
are true and complete in all material respects as of the date of each Closing: (a) the Company is a corporation duly formed, validly
existing and in good standing under the laws of the State of Nevada. The Company has all requisite power and authority to own and operate
its properties and assets, to execute and deliver this Subscription Agreement, the Shares and any other agreements or instruments required
hereunder. The Company is duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions
in which the nature of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those
jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business; (b) The issuance, sale
and delivery of the Shares in accordance with this Subscription Agreement have been duly authorized by all necessary corporate action
on the part of the Company. The Shares, when issued, sold and delivered against payment therefor in accordance with the provisions of
this Subscription Agreement, will be duly and validly issued, fully paid and non-assessable; (c) the acceptance by the Company of this
Subscription Agreement and the consummation of the transactions contemplated hereby are within the Company’s powers and have been
duly authorized by all necessary corporate action on the part of the Company. Upon the Company’s acceptance of this Subscription
Agreement, this Subscription Agreement shall constitute a valid and binding agreement of the Company, enforceable against the Company
in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other laws
of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief, or other equitable remedies and (iii) with respect to provisions relating to indemnification
and contribution, as limited by the Company’s certificate of incorporation, bylaws and the Nevada Business Corporation Act in general.
4. Representations
and Warranties of Investor. By subscribing to the Offering, Investor (and, if Investor is purchasing the Shares subscribed for hereby
in a fiduciary capacity, the person or persons for whom Investor is so purchasing) represents and warrants, which representations and
warranties are true and complete in all material respects, as of the date of each Closing:
(a)
Requisite Power and Authority. Investor has all necessary power and authority under all applicable provisions of law to
subscribe to the Offering, to execute and deliver this Subscription Agreement and to carry out the provisions thereof. All actions on
Investor’s part required for the lawful subscription to the offering have been or will be effectively taken prior to the Closing.
Upon subscribing to the Offering, this Subscription Agreement will be a valid and binding obligation of Investor, enforceable in accordance
with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application
affecting enforcement of creditors’ rights and (ii) as limited by general principles of equity that restrict the availability of
equitable remedies.
(b)
Company Offering Circular. Investor acknowledges the public availability of the Company’s Offering Circular which
can be viewed on the SEC Edgar Database, under the CIK number 0001929281. This Offering Circular is made available
in the Company’s
qualified offering statement on SEC Form 1-A, as amended, and was qualified by the SEC on _______ ______, 2022. In the Company’s
Offering Circular, it makes clear the terms and conditions of the offering of Shares and the risks associated therewith are described.
Investor has had an opportunity to discuss the Company’s business, management and financial affairs with directors, officers and
management of the Company and has had the opportunity to review the Company’s operations and facilities. Investor has also had
the opportunity to ask questions of and receive answers from the Company and its management regarding the terms and conditions of this
investment. Investor acknowledges that except as set forth herein, no representations or warranties have been made to Investor, or to
Investor’s advisors or representative, by the Company or others with respect to the business or prospects of the Company or its
financial condition.
(c)
Investment Experience; Investor Determination of Suitability. Investor has sufficient experience in financial and business
matters to be capable of utilizing such information to evaluate the merits and risks of Investor’s investment in the Shares, and
to make an informed decision relating thereto. Alternatively, the Investor has utilized the services of a purchaser representative and
together they have sufficient experience in financial and business matters that they are capable of utilizing such information to evaluate
the merits and risks of Investor’s investment in the Shares, and to make an informed decision relating thereto. Investor has evaluated
the risks of an investment in the Shares, including those described in the section of the Offering Circular entitled “Risk Factors,”
and has determined that the investment is suitable for Investor. Investor has adequate financial resources for an investment of this
character. Investor could bear a complete loss of Investor’s investment in the Company.
(d)
No Registration. Investor understands that the Shares are not being registered under the Securities Act on the ground that
the issuance is exempt under Regulation A of Section 3(b) of the Securities Act, and that reliance on such exemption is predicated in
part on the truth and accuracy of Investor's representations and warranties, and those of the other purchasers of the Shares, in the
offering. Investor further understands that, at present, the Company is offering the Shares solely by members of its management. However,
the Company reserves the right to engage the services of a broker/dealer who is registered with the Financial Industry Regulatory Authority
(“FINRA”). Accordingly, until such FINRA registered broker/dealer has been engaged as a placement or selling agent,
the Shares may not be “covered securities” under the National Securities Market Improvement Act of 1996, and the Company
may be required to register or qualify the Shares under the securities laws of those states in which the Company intends to offer the
Shares. In the event that Shares are so registered or qualified, the Company will notify the Investor and all prospective purchasers
of the Shares as to those states in which the Company is permitted to offer and sell the Shares. In the event that the Company engages
a FINRA registered broker/dealer as placement or selling agent, and FINRA approves the compensation of such broker/dealer, then the Shares
will no longer be required to be registered under state securities laws on the basis that the issuance thereof is exempt as an offer
and sale not involving a registrable public offering in such state, as the Shares will be “covered securities” under
the National Securities Market Improvement Act of 1996. The Investor covenants not to sell, transfer or otherwise dispose of any Shares
unless such Shares have been registered under the applicable state securities laws in which the Shares are sold, or unless exemptions
from such registration requirements are otherwise available.
(e)
Illiquidity and Continued Economic Risk. Investor acknowledges and agrees that there is no ready public market for the
Shares and that there is no guarantee that a market for their resale will ever exist. The Company has no obligation to list any of the
Shares on any market or take any steps (including registration under the Securities Act or the Securities Exchange Act of 1934, as amended)
with respect to facilitating trading or resale of the Shares. Investor must bear the economic risk of this investment indefinitely and
Investor acknowledges that Investor is able to bear the economic risk of losing Investor’s entire investment in the Shares.
(f)
Reserved.
(g)
Stockholder Information. In addition to providing the Investor Questionnaire attached hereto, within five (5) days after
receipt of a request from the Company, Investor hereby agrees to provide such information with respect to its status as a stockholder
(or potential stockholder) and to execute and deliver such documents as may reasonably be necessary to comply with any and all laws and
regulations to which the Company is or may become subject, including, without limitation, the need to determine the accredited investor
status of the Company’s stockholders. Investor further agrees that in the event it transfers any Shares, it will require the transferee
of such Shares to agree to provide such information to the Company as a condition of such transfer.
(h)
Valuation; Arbitrary Determination of Per Share Purchase Price by the Company. Investor acknowledges that the Per Share
Purchase Price of the Shares to be sold in this offering was set by the Company on the basis of the Company’s internal valuation
and no warranties are made as to value. Investor further acknowledges that future offerings of securities of the Company may be made
at lower valuations, with the result that Investor’s investment will bear a lower valuation.
(i)
Domicile. Investor maintains Investor’s domicile (and is not a transient or temporary resident) at the address provided
with Investors subscription.
(j)
Foreign Investors. If Investor is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue
Code of 1986, as amended), Investor hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction
in connection with any invitation to subscribe for the Shares or any use of this Subscription Agreement, including (i) the legal requirements
within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any
governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be
relevant to the purchase, holding, redemption, sale, or transfer of the Shares. Investor’s subscription and payment for and continued
beneficial ownership of the Shares will not violate any applicable securities or other laws of Investor’s jurisdiction.
(k) Fiduciary
Capacity. If Investor is purchasing the Shares in a fiduciary capacity for another person or entity, including without limitation
a corporation, partnership, trust or any other entity, the Investor has been duly authorized and empowered to execute this Agreement
and all other subscription documents. Upon request of the Company, Investor will provide true, complete and current copies of all relevant
documents creating the Investor, authorizing its investment in the Company and/or evidencing the satisfaction of the foregoing.
5. Indemnity.
The representations, warranties and covenants made by Investor herein shall survive the closing of this Subscription Agreement. Investor
agrees to indemnify and hold harmless the Company and its respective officers, directors and affiliates, and each other person, if any,
who controls the Company within the meaning of Section 15 of the Securities Act against any and all loss, liability, claim, damage and
expense whatsoever (including, but not limited to, any and all reasonable attorneys’ fees, including attorneys’ fees on appeal)
and expenses reasonably incurred in investigating, preparing or defending against any false representation or warranty or breach of failure
by Investor to comply with any covenant or agreement made by Investor herein or in any other document furnished by Investor to any of
the foregoing in connection with this transaction.
6. Governing
Law; Jurisdiction; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation of the
Offering Circular, including, without limitation, this Subscription Agreement, shall be governed by and construed and enforced in accordance
with the internal laws of the State of Nevada, without regard to the principles of conflicts of law thereof. Each party agrees that all
legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Subscription Agreement
and any documents included within the Offering Circular (whether brought against a party hereto or its respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting
in Broward County, Florida. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in Broward County, Florida for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the documents included within the Offering Circular),
and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Subscription Agreement and agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If any party hereto shall commence an action or proceeding to enforce any provisions of the documents included within the Offering
Circular, then the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys’
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
This
choice of forum provision does not preclude or contract the scope of exclusive federal or concurrent jurisdiction for any actions brought
under the Securities Act or the Exchange Act and does not apply to claims arising under the federal securities laws. Accordingly, our
exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations
thereunder, and you cannot waive our compliance with these laws, rules, and regulations.
IN
ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY,
TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL
BY JURY.
This
Waiver of Jury Trial does not waive compliance with federal securities laws and the rules and regulations promulgated thereunder. Accordingly,
this Jury Trial Waiver provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations
thereunder, and you cannot waive our compliance with these laws, rules, and regulations.
7. Notices.
Notice, requests, demands and other communications relating to this Subscription Agreement and the transactions contemplated herein shall
be in writing and shall be deemed to have been duly given if and when (a) delivered personally, on the date of such delivery; or (b)
mailed by registered or certified mail, postage prepaid, return receipt requested, in the third day after the posting thereof; or (c)
emailed on the date of such delivery to the address of the respective parties as follows, if to the Company, to BioLife Sciences
Inc., 2831 St. Rose Parkway #200, Henderson, NV USA 89052, Attention: Justin De Four, Chairman and Chief Executive Officer. If to Investor,
at Investor’s address supplied in connection with this subscription, or to such other address as may be specified by written notice
from time to time by the party entitled to receive such notice. Any notices, requests, demands or other communications by email shall
be confirmed by letter given in accordance with (a) or (b) above.
8. Purchase
Procedure. The Investor acknowledges that, in order to subscribe for Shares, he must, and he does hereby, deliver to the Company:
(a) a fully completed and executed counterpart of the Signature Page attached to this Subscription Agreement; and (b) payment for the
aggregate Purchase Price in the amount set forth on the Signature Page attached to this Agreement. Payment may be made by either check,
wire, credit card or ACH deposits.
Please
send checks to the Company.
Medical
Care Technologies Inc.
1910
S. Stapley Drive, Suite 221
Mesa,
AZ 85204
Wire
instructions:
Name
and Address of Bank:
ABA#
Account#
For
the benefit of: Medical Care Technologies Inc.
9. Miscellaneous.
All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity
of the person or persons or entity or entities may require. Other than as set forth herein, this Subscription Agreement is not transferable
or assignable by Investor. The representations, warranties and agreements contained herein shall be deemed to be made by and be binding
upon Investor and its heirs, executors, administrators and successors and shall inure to the benefit of the Company and its successors
and assigns. None of the provisions of this Subscription Agreement may be waived, changed or terminated orally or otherwise, except as
specifically set forth herein or except by a writing signed by the Company and Investor. In the event any part of this Subscription Agreement
is found to be void or unenforceable, the remaining provisions are intended to be separable and binding with the same effect as if the
void or unenforceable part were never the subject of agreement. The invalidity, illegality or unenforceability of one or more of the
provisions of this Subscription Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder
of this Subscription Agreement in such jurisdiction or the validity, legality or enforceability of this Subscription
Agreement, including
any such provision, in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable
to the fullest extent permitted by law. This Subscription Agreement supersedes all prior discussions and agreements between the parties,
if any, with respect to the subject matter hereof and contains the sole and entire agreement between the parties hereto with respect
to the subject matter hereof. The terms and provisions of this Subscription Agreement are intended solely for the benefit of each party
hereto and their respective successors and assigns, and it is not the intention of the parties to confer, and no provision hereof shall
confer, third-party beneficiary rights upon any other person. The headings used in this Subscription Agreement have been inserted for
convenience of reference only and do not define or limit the provisions hereof. In the event that either party hereto shall commence
any suit, action or other proceeding to interpret this Subscription Agreement, or determine to enforce any right or obligation created
hereby, then such party, if it prevails in such action, shall recover its reasonable costs and expenses incurred in connection therewith,
including, but not limited to, reasonable attorney’s fees and expenses and costs of appeal, if any. All notices and communications
to be given or otherwise made to Investor shall be deemed to be sufficient if sent by e-mail to such address provided by Investor on
the signature page of this Subscription Agreement. Unless otherwise specified in this Subscription Agreement, Investor shall send all
notices or other communications required to be given hereunder to the Company by email to ir@biolifesciences.com followed by a
copy via FedEx or other national overnight courier service. Any such notice or communication shall be deemed to have been delivered and
received on the first business day following that on which the e-mail has been sent (assuming that there is no error in delivery). As
used in this Section 9, the term “business day” shall mean any day other than a day on which banking
institutions in the State of California are legally closed for business. This Subscription Agreement may be executed in one or more counterparts.
No failure or delay by any party in exercising any right, power or privilege under this Subscription Agreement shall operate as a waiver
thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other
right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided
by law.
10. Consent
to Electronic Delivery of Notices, Disclosures and Forms. Investor understands that, to the fullest extent permitted by law, any
notices, disclosures, forms, privacy statements, reports or other communications (collectively, “Communications”)
regarding the Company, the Investor’s investment in the Company and the shares of Common Stock (including annual and other updates
and tax documents) may be delivered by electronic means, such as by e-mail. Investor hereby consents to electronic delivery as described
in the preceding sentence. In so consenting, Investor acknowledges that e-mail messages are not secure and may contain computer viruses
or other defects, may not be accurately replicated on other systems or may be intercepted, deleted or interfered with, with or without
the knowledge of the sender or the intended recipient. The Investor also acknowledges that an e-mail from the Company may be accessed
by recipients other than the Investor and may be interfered with, may contain computer viruses or other defects and may not be successfully
replicated on other systems. Neither the Company, nor any of its respective officers, directors and affiliates, and each other person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act (collectively, the “Company Parties”),
gives any warranties in relation to these matters. Investor further understands and agrees to each of the following: (a) other than with
respect to tax documents in the case of an election to receive paper versions, none of the Company Parties will be under any obligation
to provide Investor with paper versions of any Communications; (b) electronic Communications may be provided to Investor via e-mail or
a website of a Company Party upon written notice of such website’s internet address to such Investor. In order to view and retain
the Communications, the Investor’s computer hardware and software must, at a minimum, be capable of accessing the Internet, with
connectivity to an internet service provider or any other capable communications medium, and with software capable of viewing and printing
a portable document format (“PDF”) file created by Adobe Acrobat. Further, the Investor must have a personal e-mail
address capable of sending and receiving e-mail messages to and from the Company Parties. To print the documents, the Investor will need
access to a printer compatible with his or her hardware and the required software; (c) if these software or hardware requirements change
in the future, a Company Party will notify the Investor through written notification. To facilitate these services, the Investor must
provide the Company with his or her current e-mail address and update that information as necessary. Unless otherwise required by law,
the Investor will be deemed to have received any electronic Communications that are sent to the most current e-mail address that the
Investor has provided to the Company in writing; (d) none of the Company Parties will assume liability for non-receipt of notification
of the availability of electronic Communications in the event the Investor’s e-mail address on file is invalid; the Investor’s
e-mail or Internet service provider filters the notification as “spam” or “junk mail”; there is
a malfunction in the Investor’s computer, browser, internet service or software; or for other reasons beyond the control of the
Company Parties; and (e) solely with respect to the provision of tax documents by a Company Party, the Investor agrees to each of the
following: (i) if the Investor does not consent to receive tax documents electronically, a paper copy will be provided, and (ii) the
Investor’s consent to receive tax documents electronically continues for every tax year of the Company until the Investor withdraws
its consent by notifying the Company in writing.
[THIS
SPACE IS INTENTIONALLY LEFT BLANK]
[SIGNATURE
PAGE TO FOLLOW]
INVESTOR
CERTIFIES THAT HE HAS READ THIS ENTIRE SUBSCRIPTION AGREEMENT AND THAT EVERY STATEMENT MADE BY THE INVESTOR HEREIN IS TRUE AND COMPLETE.
THE
COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE
OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED. THE INFORMATION PRESENTED IN THE OFFERING MATERIALS WAS PREPARED BY THE
COMPANY SOLELY FOR THE USE BY PROSPECTIVE INVESTORS IN CONNECTION WITH THIS OFFERING. NO REPRESENTATIONS OR WARRANTIES ARE MADE AS TO
THE ACCURACY OR COMPLETENESS OF THE INFORMATION CONTAINED IN ANY OFFERING MATERIALS, AND NOTHING CONTAINED IN THE OFFERING MATERIALS
IS OR SHOULD BE RELIED UPON AS A PROMISE OR REPRESENTATION AS TO THE FUTURE PERFORMANCE OF THE COMPANY.
THE
COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF
THE OFFERING AND/OR ACCEPT OR REJECT, IN WHOLE OR IN PART, FOR ANY REASON OR FOR NO REASON, ANY PROSPECTIVE INVESTMENT IN THE SECURITIES
OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE DOLLAR AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE
INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES,
CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.
IN
WITNESS WHEREOF, this Subscription Agreement is executed as of the ______ day of _________, 2024.
Investor Name: |
|
|
|
Number of Shares Subscribed
For: |
|
|
|
Total Purchase Price: |
$ |
|
|
Signature of Investor: |
|
Name
of Signer |
|
|
|
Title of Signer |
|
|
|
Address of Investor: |
|
|
|
E-Mail Address: |
|
|
|
Investor’s SS# or
Tax ID#: |
|
ACCEPTED
BY: MEDICAL CARE TECHNOLOGIES INC.
Signature
of Authorized Signatory: __________________________________
Name
of Authorized Signatory: ___________________________, CEO
Date
of Acceptance: _________________, 2024.
[Signature
Page to Subscription Agreement]
INVESTOR
QUESTIONNAIRE (US INVESTORS)
Name
of Subscriber: _________________________________________________________________
The
offer and sale of securities of MEDICAL CARE TECHNOLOGIES INC. (the “Company”), is not being registered under the
Securities Act of 1933, as amended (the “1933 Act”) or qualified under state securities laws, in reliance upon exemptions
from such registration and qualification requirements for transactions not involving any public offering. Information supplied through
this Questionnaire will be used to ensure compliance with the requirements of such exemptions.
The
Subscriber represents and warrants to the Company that: (a) The information contained herein is complete and accurate and may be relied
upon by the Company; and (b) Subscriber will notify the Company immediately of any material change in any information contained herein
occurring prior to the acceptance or rejection of the Subscriber’s subscription for Units of the Company.
ALL
INFORMATION ON WILL BE TREATED CONFIDENTIALLY
(Please print and attach additional pages where necessary to fully answer questions.)
INSTRUCTIONS:
IF
THE SUBSCRIBER IS A PARTNERSHIP, PLEASE ATTACH AN EXECUTED COPY OF THE PARTNERSHIP AGREEMENT AND ALL AMENDMENTS THERETO.
IF
THE SUBSCRIBER IS A LIMITED LIABILITY COMPANY, PLEASE ATTACH AN EXECUTED COPY OF THE OPERATING AGREEMENT AND ALL AMENDMENTS THERETO.
IF
THE SUBSCRIBER IS A CORPORATION, PLEASE ATTACH A COPY OF THE ARTICLES OF INCORPORATION AND BY-LAWS OF THE CORPORATION (AND ALL AMENDMENTS
THERETO) AND A BOARD OF DIRECTORS RESOLUTION (CERTIFIED BY THE SECRETARY OF THE CORPORATION) AUTHORIZING THE INVESTMENT.
IF
THE SUBSCRIBER IS A TRUST, PLEASE ATTACH A COPY OF THE TRUST AGREEMENT AND ALL AMENDMENTS THERETO.
IF
THE SUBSCRIBER IS AN ERISA PLAN, PLEASE ATTACH A COPY OF THE PLAN AND A COPY OF THE RESOLUTION REQUIRED BY THE PLAN AUTHORIZING THE INVESTMENT
DULY EXECUTED BY THE PLAN FIDUCIARY.
For
each of the categories listed below, place your initials on the line “Yes” or “No”, as the case may be, to indicate
whether you qualify as an Accredited Investor.
1. Are
you are broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934?
Yes
[ ] No [ ]
2. Are
you an investment company registered under the Investment Company Act of 1940 or a business development company as defined in section
2(a)(48) of the Investment Company Act of 1940?
Yes
[ ] No [ ]
3. Are
you an employee benefit plan within the meaning of Title I of the employee Retirement Income Security Act of 1974 (other than a pension
or profit-sharing trust of the issuer, a self-employed individual retirement plan or individual retirement account) the investment decision
for which is made by a plan fiduciary, as defined in section 3(21) of such Act, which is either a bank, savings and loan association,
insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if
a self-directed plan, with investment decisions made solely by persons that are accredited investors?
Yes
[ ] No [ ]
4. A
private business development company as defined in section 202(a) (22) of the Investment Advisor Act of 1940?
Yes
[ ] No [ ]
5. Are
you a director, executive officer, or general partner of the Company?
Yes
[ ] No [ ]
6. Are
you a natural person (not an entity) whose individual net worth, or joint net worth with your spouse, exceeds $1 million (excluding the
value of your primary residence)?
Yes
[ ] No [ ]
7. Are
you a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with your
spouse in excess of $300,000 in each of those years and a reasonable expectation of reaching the same income level in the current year?
Yes
[ ] No [ ]
8. Are
you a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose
purchase is directed by a sophisticated person (a sophisticated person being one who has such knowledge and experience in business and
financial matters that he is capable of evaluating the merits and risk of the prospective investment)?
Yes
[ ] No [ ]
9. Are
you an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, or Massachusetts of similar trust, or partnership,
not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000?
Yes
[ ] No [ ]
10. Do
you otherwise qualify as an accredited investor pursuant to Rule 501 of Regulation D of the Securities Act of 1933 or any other section
of the Act?
Yes
[ ] No [ ]
If
“yes”, please describe basis of qualification: ________________________________________
11. Lack
of Qualification. I do not meet any of the above standards.
Yes
[ ] No [ ]
If
you answered yes to number 11, above, please complete the following:
Non-Accredited
Investor Disclosure: (Please Initial Each Line):
_____ Although
not an Accredited Investor, I have such knowledge and experience in financial and business matters that it is are capable of evaluating
the merits and risks of an investment in the Common Stock on the basis of its investment experience, business experience, professional
experience, and/or education or have discussed with my attorney, accountant or other advisor (a “Purchaser Representative”)
who is knowledgeable and experienced in such matters whether an investment in the Series B Membership Interest is appropriate in light
of my financial circumstances and have received the advice of such Purchaser Representative with respect to the merits and risks of such
an investment. Together with such Purchaser Representative, and with the benefit of his advice, I have such knowledge and experience
in financial and business matters that he or she is capable of evaluating the merits and risks of an investment in the Common Stock.
_____ I
have consulted with an outside adviser such as an attorney or accountant (a “Purchaser Representative”) with regard to my
investment in the Company.
_____
I or my Purchaser Representative have been given the opportunity to speak with the officers of the Company and ask any questions
of them, and receive answers from them, about the Company.
___
I understand that the Company has not produced any revenue, is in the startup stage and does not have audited financial statements,
but that I will receive financial statements once the Company begins producing them.
____ I
or my Purchaser Representative been given the opportunity to obtain any additional information necessary to verify the accuracy of the
information supplied to us.
[SIGNATURE
PAGE FOLLOWS]
IN
WITNESS WHEREOF, the undersigned has executed this Subscription Agreement this day of__, 2024.
FOR
EXECUTION BY AN INDIVIDUAL:
|
|
|
Signature
of Investor |
|
Tax Identification or
Social Security Number |
|
|
|
Name
of Investor - Please Print |
|
Telephone
Number - Home |
|
|
|
Address |
|
Telephone
Number - Business |
|
|
|
City,
State and Zip Code |
|
|
FOR
EXECUTION BY AN ENTITY:
Print
Name of Entity: _____________________________________ |
|
|
|
|
|
|
|
|
By: __________________________________________________ |
|
|
Name:
________________________________________________ |
|
|
Title:
_________________________________________________ |
|
|
Date:_________________________________________________ |
|
|
|
|
|
Business
address: _______________________________________ |
|
|
|
|
|
Business phone number: ( )_________________________________ |
|
|
Business fax number:
( ) ___________________________________ |
|
|
Business
email address: ___________________________________ |
|
|
Tax Identification Number: _________________________________ |
|
|
|
|
|
Anti-Money Laundering Certification
This section must be completed for the subscriber-beneficial
investor. For more information, see AML Definitions section below.
By initialing below, I hereby represent and certify that I am not involved in any money laundering scheme and that my investment funds
have not been directly or indirectly derived from activities that may contravene U.S. or international laws, rules and regulations designed
to avoid money laundering, including, without limitation, the provisions of the Bank Secrecy Act of 1970, as amended. Neither I
nor any person controlling, controlled by, or under common control with me, nor any person having a beneficial interest in my investments,
is a country, territory, person or entity named on the U.S. Department of Treasury’s Office of Foreign Asset Control list, or is
a person or entity that resides or has a place of business in a country or territory named in such lists. I agree to notify you promptly
should I become aware of any changes to the information set forth in this statement. I acknowledge that, due to anti-money laundering
requirements operating in the United States and the particular fund’s own internal anti-money laundering policies, such fund may
require further identification from me and the source of the investment funds before any subscriptions can be processed, monies accepted
or a redemption request processed. I shall hold the fund, the investment adviser and each of its respective principals, members, directors,
officers, and employees harmless and indemnified against any loss arising as a result of a failure to process this Questionnaire or a
redemption application if any information that has been required by an indemnified party has not been satisfactorily provided by me. I
further acknowledge that all subscription payments transferred to a fund must originate directly from a bank or brokerage account in my
name.
If I am (1) acting as trustee, agent, representative or disclosed nominee for another person or entity, or (2) an entity investing on
behalf of underlying investors (including a fund-of-funds), other than a publicly traded company listed on an organized exchange (or a
subsidiary or a pension fund of such a company) based in a Financial Action Task Force (FATF) Compliant Jurisdiction (hereinafter referred
collectively as Beneficial Owners), I represent and warrant that:
☐
I understand and acknowledge the representations, warranties and agreements made herein are made by me with respect to me, and with respect
to the Beneficial Owners.
☐
I have all requisite power and authority from the Beneficial Owners to execute and perform the obligations under this Questionnaire and
Registered User’s Agreement.
☐
I have adopted and implemented anti-money laundering policies, procedures and controls that comply with, and will continue to comply in
all respects with, the requirements of applicable anti-money laundering laws and regulations.
☐
I have established or have access to the identity of all Beneficial Owners, hold evidence of or have access to such identities, and will
make such information available to a fund upon request, and have procedures in place to ensure that the Beneficial Owners are not Prohibited
Investors.
I Agree
_____________________
(Subscriber Initials)
ANTI-MONEY LAUNDERING DEFINITIONS |
FATF—Financial Action Task Force on Money Laundering.
FATF-Compliant Jurisdiction—one that is a member in good standing
of FATF and has undergone two rounds of FATF mutual evaluations.
Non-Cooperative Jurisdiction—any non-U.S. country that has
been designated as non-cooperative with international anti-money laundering principles or procedures by an intergovernmental group or
organization, such as the FATF, of which the United States is a member and with which designation the United States representative to
the group or organization continues to concur.
Foreign Bank—an entity that is organized under the laws of
a non-U.S. country, engages in the business of banking, is recognized as a bank by the bank supervisory or monetary authority of the country
of its organization or principal banking operations, receives deposits to a substantial extent in the regular course of its business,
and has the power to accept demand deposits, but does not include the U.S. branches or agencies of a non-U.S. bank.
Foreign Shell Bank—a Foreign Bank without a physical presence
in any country, excluding a Regulated Affiliate.
Regulated Affiliate—a Foreign Shell Bank that is an affiliate
of a depository institution, credit union, or Foreign Bank that maintains a physical presence in the United States or a non-U.S. country,
as applicable, and is subject to supervision by a banking authority in the country regulating such affiliated depository institution,
credit union, or Foreign Bank.
Physical Presence—a place of business maintained by a Foreign
Bank and located at a fixed address, other than solely a post office box or an electronic address, in a country in which the Foreign Bank
is authorized to conduct banking activities, and at which location the Foreign Bank employs one or more individuals on a full-time basis,
maintains operating records related to its banking activities, and is subject to inspection by the banking authority that licensed the
Foreign Bank to conduct banking activities.
Prohibited Investor—(1) a person or entity whose name appears
on the various lists issued and maintained by the U.S. Office of Foreign Assets Control (OFAC), including the List of Specially Designated
Nationals and Blocked Persons, the Specially Designated Terrorists List and the Specially Designated Narcotics Traffickers List; (2) a
Foreign Shell Bank; or (3) a person or entity who is a citizen or resident of, or which is located in, or whose subscription funds are
transferred from or through, a Foreign Bank in a Non-Cooperative Jurisdiction or Sanctioned Regime.
Sanctioned Regimes—targeted foreign countries, terrorism-sponsoring
organizations and international narcotics traffickers in respect of which OFAC administers and enforces economic and trade sanctions based
on U.S. foreign policy and national security goals.
USA Patriot Act—the Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism (USA PATRIOT) Act of 2001 (Pub. L. No. 107-56).
Exhibit 12.1
|
18305 BISCAYNE BLVD. |
|
SUITE 200 |
JONATHAN D. LEINWAND, P.A. |
AVENTURA, FL 33160 |
|
TEL: (954) 903-7856 |
|
FAX: (954) 252-4265 |
|
|
|
E-MAIL: JONATHAN@JDLPA.COM |
August 8, 2024
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221
Mesa, AZ 85204
Ladies and Gentlemen:
We are acting as counsel to Medical Care Technologies
Inc., a Nevada corporation (“MDCE”), for the purpose of rendering an opinion as to the legality of the shares of MDCE’s
common stock (the “Shares”), to be offered and distributed by MDCE pursuant to an offering statement to be filed under Regulation
A of the Securities Act of 1933, as amended, by MDCE, with the U.S. Securities and Exchange Commission (the “SEC”) on Form
1-A, for the purpose of qualifying the offer and sale of the Shares (“Offering Statement”).
The offering statement, and pre-qualification amendments,
cover the contemplated sale of up to $1,000,000 in Shares of its Common Stock at a price of $[ ] per share.
In connection with the opinion contained herein, we
have examined the offering statement, as well as pre-qualification amendments, the certificate of incorporation (as amended) and bylaws,
the resolutions of the MDCE’s board of directors and stockholders, as well as all other documents necessary to render an opinion.
In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of
all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic
copies and the authenticity of the originals of such copies.
Based upon the foregoing, we are of the opinion that
the entirety of the Shares being sold pursuant to the offering statement are duly authorized and will be, when issued in the manner described
in the offering statement, legally and validly issued, fully paid, and non-assessable.
No opinion is being rendered hereby with respect to
the truth and accuracy, or completeness of the offering statement or any portion thereof.
We further consent to the use of this opinion as an
exhibit to the offering statement and to the reference to our firm under the caption “Legal Matters” in the offering circular.
We assume no obligation to update or supplement any of the opinion set forth herein to reflect any changes of law or fact that may occur
following the date hereof.
|
Very Truly Yours, |
|
|
|
JONATHAN D. LEINWAND, P.A. |
|
|
|
|
By: |
/s/ Jonathan Leinwand |
|
|
Jonathan Leinwand, Esq. |
Medical Care Technologies (PK) (USOTC:MDCE)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Medical Care Technologies (PK) (USOTC:MDCE)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024